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ABSTRACT 
 
Clinical characteristics and neuroanatomical predictors of acute antidepressant outcome for 
patients with comorbid depression and mild cognitive impairment 
by 
Jeffrey N. Motter 
Advisor: Joel Sneed 
 
Background: Older adults presenting with both a depressive disorder (DEP) and cognitive 
impairment (CI) represent a unique, understudied population. The classification of cognitive 
impairment severity continues to be debated though it has recently been subtyped into late 
(LMCI) versus early (EMCI) stages. Previous studies have found associations between treatment 
outcome and both cortical thickness and white matter hyperintensities (WMH), though report 
inconsistent directionality and affected regions. In this study, we examined baseline clinical 
characteristics and neuroanatomical features as prognostic indicators for older adults with 
comorbid DEP and CI participating in an open antidepressant trial. EMCI is hypothesized to have 
greater cortical thickness and global cognition than LMCI. Antidepressant treatment remitters 
and responders are hypothesized to have greater cortical thickness and lower WMH burden 
than non-remitters and non-responders. 
Methods: Key inclusion criteria were diagnosis of major depression or dysthymic disorder with 
Hamilton Depression Rating Scale (HDRS) score >14, and cognitive impairment defined by 
 v 
 
 
MMSE score ≥21 and impaired performance on the WMS-R Logical Memory II test. Patients 
were classified as EMCI or LMCI based on the 1.5 SD cutoff on tests of verbal memory, and 
compared on baseline clinical, neuropsychological, and anatomical characteristics. All patients 
underwent a baseline MRI scan and received open antidepressant treatment for 8 weeks. 
Cortical thickness was extracted using an automated brain segmentation and reconstruction 
program (FreeSurfer). Vertex-wise analyses were conducted using general linear models to 
evaluate the relationships between cortical thickness and clinical variables. 
Results: 79 DEP-CI patients were recruited, of whom 39 met criteria for EMCI and 40 for LMCI. 
The mean age was 68.9 and mean HDRS was 23.0. LMCI patients had significantly worse global 
cognition and smaller right hippocampal volume compared to EMCI patients. EMCI patients had 
thicker right medial orbitofrontal cortex than LMCI. MRI indices of cerebrovascular disease did 
not differ between MCI subtypes. Remitters had greater deep WMH burden, left medial 
orbitofrontal gyrus thickness, and right superior frontal gyrus thickness than non-remitters. 
Greater HDRS depressive severity was positively correlated with right pars triangularis 
thickness. Stronger ADAS-Cog global cognitive performance was positively correlated with 
thickness in diffuse cortical areas. 
Conclusions: Cognitive and neuronal loss markers differed between EMCI and LMCI among 
patients with DEP-CI, with LMCI being more likely to have the clinical and neuronal loss markers 
known to be associated with Alzheimer’s disease. Samples of DEP-CI exhibit unique patterns of 
cortical thickness and WMHs compared to their non-CI peers. Cortical thickness may serve as 
predictor of treatment remission and relates to both depressive severity and global cognition. 
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Introduction 
Depression and Cognitive Impairment 
 Depression (DEP) and cognitive impairment (CI) are the most common neuropsychiatric 
disorders in older adults, with a co-occurrence that may exceed chance (Arve, Tilvis, Lehtonen, 
Valvanne, & Sairanen, 1999; Burt, Zembar, & Niederehe, 1995). Patients presenting with DEP-CI 
represent a unique, understudied population that is difficult to diagnose, treat and estimate 
prognosis. CI is associated with poor antidepressant response in depressed older adults (Sneed 
et al., 2007). In most but not all studies, DEP in individuals with CI increases the risk of 
transition to a diagnosis of dementia (Devanand et al., 1996; Wilson et al., 2002). DEP-CI 
patients convert to dementia at a greater rate than elderly non-depressed patients with mild 
cognitive impairment (MCI) (Chung et al., 2016), lending support to the idea that late-life DEP 
may be a risk factor for later dementia or represent a prodromal condition in many patients 
with dementia because DEP symptoms often accompany rather than precede cognitive decline 
(Mourao, Mansur, Malloy-Diniz, Castro Costa, & Diniz, 2016).  
The underlying mechanism driving the association between DEP and CI is unclear. 
Disruption in mood may be a symptom of the same underlying pathology contributing to 
dementia, be it frontotemporal dementia, subcortical dementia, or Alzheimer’s disease (AD). In 
addition to affecting cholinergic systems (Mufson, Counts, Perez, & Ginsberg, 2008), it is 
possible that progressive neurodegenerative disease affects serotonergic and noradrenergic 
systems as well (Huey, Putnam, & Grafman, 2006), each of which has been linked with 
depressive disorders. DEP is a risk factor for dementia (Mourao et al., 2016), and is associated 
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with quickened progression from MCI to dementia (Chung et al., 2015), yet DEP symptoms 
accompany rather than precede initial CIs (Richard et al., 2013). This indicates a shared rather 
than chronologically separate pathology. The linkage of DEP and cognitive symptoms is further 
evidenced by their tendency to change in unison. Indeed, successful antidepressant treatment 
leads to improvement in cognition, whereas antidepressant nonresponse is associated with 
residual cognitive deficits (Sneed et al., 2007). Despite these consequences, there is little data 
on the efficacy of antidepressants for improving mood and cognitive enhancers for restoring 
cognitive deficits in this population. 
 
Treatment of MCI and DEP 
 Antidepressant treatment for DEP predominantly consists of selective serotonin 
reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). 
Norepinephrine reuptake inhibitors, monoamine oxidase inhibitors (MAOIs), tricyclics, and 
atypical antidepressants (such as bupropion) are also used, albeit less frequently. The 
mechanism of action for antidepressants typically involves blocking the reuptake of one or 
more neurotransmitters, which allows them to persist in the synapse for a longer duration and 
facilitates increased odds of receptor binding. This also serves to indirectly affect receptor tone 
and density, which alters the threshold for future signaling (Celada, Puig, Amargos-Bosch, Adell, 
& Artigas, 2004). These secondary adaptive mechanisms that occur following reuptake 
inhibition may be responsible for the delayed action of antidepressants, which take up to 2-3 
weeks for earliest observation of clinically significant effects. Approximately 50% of depressed 
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older adults will not reach remission during the course of the first treatment (Roose & 
Schatzberg, 2005), with even worse prognosis for those aged 65 or older (Tedeschini et al., 
2011). Further, the primary outcome variables in treatment trials pertain to depressive severity, 
with few drug design considerations given to the impact of antidepressants on cognitive 
abilities. 
Treatment for CI principally involves cholinesterase inhibitors, which block the enzyme 
cholinesterase from breaking down acetylcholine in the synaptic cleft. This prolongs the 
duration that acetylcholine persists in the synaptic cleft and increases its concentration. 
Successful cholinergic binding has been implicated with an array of cognitive functions, and in 
particular, verbal memory. Acetylcholinesterase activity in frontal lobe and limbic system 
structures including the right posterior cingulate cortex, left middle frontal gyrus, and right 
interior frontal gyrus is negatively correlated with retention of verbal information over time 
(Richter et al., 2014). In both MCI and AD patients, there is dysfunction in the cholinergic 
system stemming from cholinergic cell loss (Bohnen, Grothe, Ray, Muller, & Teipel, 2018; 
Haense et al., 2012). Although there have been mixed results in treating AD patients with 
cholinesterase inhibitors, some promise lies in preventing or delaying the onset of AD 
pathology. Indeed, MCI patients treated with donepezil have a 45% reduction in rate of 
hippocampal atrophy compared to those treated with placebo (Dubois et al., 2015). However, a 
previous trial of combined antidepressant + cholinesterase inhibitors in patients with DEP-CI 
found small cognitive benefits and an increased risk of recurrence of DEP episodes for patients 
receiving donepezil versus placebo (Reynolds et al., 2011). 
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MCI Subtypes 
CI varies by severity and by the types of cognitive domains impacted. At the mild end of 
the spectrum is MCI. MCI diagnostically requires both subjective self-report of cognitive decline 
and objective reduction in neuropsychological testing performance compared to normative 
data. Early approaches to classifying elderly patients without dementia as either cognitively 
normal or as MCI were based on clinical rating scale assessments such as the Clinical Dementia 
Rating scale (CDR) (Hughes, Berg, Danziger, Coben, & Martin, 1982)  and the Global 
Deterioration Scale (GDS) (Reisberg, Ferris, de Leon, & Crook, 1982). Cognitively normal 
individuals have CDR scores of 0 and GDS scores of 1 or 2, whereas MCI patients have CDR 
scores of 0.5 and GDS scores of 3. Although criteria for objective decline in cognitive functioning 
varies considerably across studies, MCI is most commonly characterized by performance on 
neuropsychological tests between 1.0 – 1.5 standard deviations (SDs) below mean for their age, 
education, and culturally appropriate normative data (Albert et al., 2011). This mild impairment 
must be observed in at least one cognitive domain, such as memory, executive functioning, 
language and visuospatial skills. Verbal memory impairment is most prevalent amongst patients 
who later convert to AD dementia. Patients with MCI may experience mild problems while 
completing complex tasks which they used to perform more easily in the past. However, they 
generally retain their ability to independently manage their activities of daily living, such as 
cleaning and maintaining their home, managing their money, preparing meals, and taking 
medications. MCI is distinguished from more severe CI and dementia by the extent of 
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impairment and level of independence in daily functioning. Severe CI generally entails testing 
performance more than 2.0 SDs below the normative mean and is met with a significant 
decrease in ability to function independently. Patients with dementia receive CDR ratings of 1 
or greater and GDS ratings ranging from 4-7 based on severity. 
Within MCI, amnestic (aMCI) and non-amnestic (naMCI) subtypes have been delineated. 
aMCI is characterized by poor performance on delayed memory tests relative to standardized 
norms, whereas naMCI is characterized by poor performance in cognitive domains other than 
memory (Petersen, 2004; Winblad et al., 2004). Patients with aMCI are thought to be more 
likely to transition to a clinical diagnosis of AD, whereas patients with naMCI are considered to 
be more likely to transition to non-AD dementia, such as vascular dementia or dementia with 
Lewy bodies (Ferman et al., 2013). Due to growing interest in early intervention and prediction, 
aMCI has been further subtyped into early aMCI (EMCI) and late aMCI (LMCI). While 
distinctions between aMCI and naMCI have been extensively studied (Csukly et al., 2016), little 
information is available on the distinction between EMCI and LMCI, and, in particular, there is a 
lack of information on differences between the two conditions in the presence of comorbid 
DEP.   
EMCI and LMCI subtypes are distinguished by the severity of amnestic impairment 
rather than age. Both diagnostically require a subjective self-report of memory decline 
alongside objective reductions in measured memory performance. EMCI requires a subjective 
self-report of memory decline and memory test performance greater than 1.0 standard 
deviations below the normative average. LMCI requires subjective self-report of memory 
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decline as well as memory test performance greater than 1.5 standard deviations below the 
norm.  These classifications have been used in the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) studies, and are related to the distinction between aMCI and naMCI that is the 
predominant subtyping classification in the literature on MCI (Aisen et al., 2010).  While LMCI is 
essentially synonymous with the longstanding definition of amnestic MCI, EMCI does not 
necessarily equate with non-amnestic MCI in which deficits in non-memory cognitive domains 
need to reach the 1.5 SD threshold (Albert et al., 2011). EMCI patients have milder verbal 
memory impairment than LMCI and are thought to represent a very early stage of disease that 
may be optimal for disease-modification treatments. These subtype differences may have 
implications for discrepancies in biomarker abnormalities, likely clinical course, and treatment 
response in patients with comorbid DEP and CI. 
 
Structural Abnormalities in MCI 
A number of neuroanatomical factors have been identified as predictors of the 
transition from MCI to AD. The medial temporal lobe contains multiple regions involved in 
declarative memory. Amongst these are the hippocampus, parahippocampal gyrus, and 
entorhinal cortex. In MCI, and to a greater extent AD, there is volumetric loss in these areas, 
which is associated with poor performance on measures of verbal learning, memory, and 
olfactory identification. In patients with MCI, those who convert to AD have greater rate of 
atrophy in the hippocampus and entorhinal cortex than those who remain cognitively stable 
(Jack et al., 2004). Further, those with DEP-CI who transition to a clinical diagnosis of AD do so 
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at a younger age and with greater hippocampal volume loss than patients with MCI alone 
(Chung et al., 2015). Taken together, these reports suggest that volumetric atrophy in the 
medial temporal lobe increases the risk of transition to AD, and DEP symptoms may exacerbate 
this tendency. 
In addition to using volumetric-based approaches, grey matter loss within the cerebral 
cortex can also be evaluated by surface-based morphometry, a viable alternative approach that 
yields cortical thickness and surface area. Surface-based morphometric analyses have multiple 
advantages over volumetric-based approaches. The curved geometry of the cerebral cortex 
leads to instances where the distance between two points along the cortex will be substantially 
underestimated when measured using 3-D volumetrics. Surface-based morphometry 
reconstructs complex and folded 2-D surfaces which allows for superior spatial localization of 
cortical regions (Fischl, Sereno, & Dale, 1999). Accordingly, scans from different subjects can be 
registered to one another using surface-based representations without the use of spatial 
smoothing as required by volume-based methods, thereby preventing loss of spatial resolution 
(Ashburner & Friston, 2000). Surface models allow for sub-voxel accuracy (Fischl & Dale, 2000) 
as well as robustness to different magnetic field strengths and scanner manufacturers (Han et 
al., 2006). However, surface-based morphometry has substantially higher computational 
demands than volumetric based approaches, resulting in a longer time required to process each 
scan. 
Cortical thickness can be derived from surface-based morphometry and is an index of 
grey matter well-suited for use in older-adult populations. Cortical thickness is the distance 
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between the grey-white matter interface and the pia mater. Compared to volume and surface 
area, cortical thickness performs equally well at diagnostically separating clinically normal older 
adults from AD populations (Schwarz et al., 2016), though is a more sensitive measure for 
detecting age-associated decline in grey matter (Hutton, Draganski, Ashburner, & Weiskopf, 
2009), and is uncorrelated with total intracranial volume (whereas grey matter volume 
measures are correlated). 
 
Cortical Thickness in MCI 
Compared to healthy controls, cortical thickness is reduced in patients with MCI and to 
an even greater extent in patients with AD (Julkunen et al., 2010) . For patients with MCI, wide 
ranges of cortical regions have been reported as reduced compared to healthy controls, 
possibly owing to the diverse etiologies that may contribute to the development of MCI. The 
regions with the most consistently reduced thickness are the frontal lobe, temporal lobe, and 
limbic system. Specifically, MCI patients have thinner bilateral middle frontal gyrus, 
parahippocampal gyrus, hippocampus, paracentral gyrus, postcentral gyrus, posterior cingulate 
gyrus, precentral gyrus, rostral superior middle frontal gyrus, caudal superior frontal gyrus, 
temporal pole, and transverse temporal gyrus compared to healthy controls (C. Li et al., 2011). 
Comparisons between EMCI and LMCI subtypes have found greater cortical thinning in the right 
superior prefrontal, medial temporal, posterior cingulate, and lateral parietal cortices for LMCI 
compared to EMCI (Ye et al., 2014).  Cortical thinning is also linked with poor performance on 
cognitive measures (Eliassen, Reinvang, Selnes, Fladby, & Hessen, 2017; Yao et al., 2012). Lower 
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mean cortical thickness is associated with lower letter fluency, semantic fluency, processing 
speed, word retrieval, and visuospatial functioning (Kim et al., 2014).  Critically, reduction in 
cortical thickness is a predictor of increased risk of conversion to dementia (Bakkour, Morris, & 
Dickerson, 2009; Hilal et al., 2015; Julkunen et al., 2010; Julkunen et al., 2009; Pacheco, Goh, 
Kraut, Ferrucci, & Resnick, 2015; Peters, Villeneuve, & Belleville, 2014). Thinner middle 
temporal gyrus and inferior parietal cortex are risk factors for progression from MCI to AD 
(Korolev, Symonds, Bozoki, & Alzheimer's Disease Neuroimaging, 2016).  
The presence of DEP symptoms in patients with MCI is associated with reduced 
entorhinal cortex thickness, and additionally may serve as markers of longitudinal atrophy, with 
greater symptoms being associated with accelerated anterior cingulate cortex atrophy over 
time (Zahodne et al., 2013). The anterior cingulate cortex is broadly involved with executive 
functions and specifically monitors for the presence of response conflict processes and 
activates the dorsolateral prefrontal cortex to resolve the conflict using adjustment processes 
(i.e., such as the inhibition of responses to task-irrelevant stimuli)(Milham, Banich, & Barad, 
2003). 
 
Structural Abnormalities in DEP 
Reductions in frontal-limbic structure volumes are found in patients with DEP. A meta-
analysis of 27 articles comparing patients with late-life DEP  to healthy controls revealed grey 
matter volume reductions in the hippocampus, orbitofrontal cortex, putamen, and thalamus 
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(Sexton, Mackay, & Ebmeier, 2013). Disruptions in white matter tracts between the 
hippocampus and orbitofrontal cortex (known as the uncinated fasciculus) as well as within the 
dorsolateral prefrontal cortex have also been reported (Wen, Steffens, Chen, & Zainal, 2014). 
White matter hyperintensities (WMH) in the deep white and periventricular regions are 
commonly found in late life DEP (Smagula & Aizenstein, 2016) and predict antidepressant 
treatment nonresponse (Sneed et al., 2011) 
 
Vascular DEP 
Cerebrovascular disease, which is a risk factor for both late-life DEP and dementia, may 
contribute to the development of both conditions by disrupting the prefrontal system. The 
harmful influence of cerebrovascular disease on prefrontal systems is important to consider in 
the context of late-life DEP and dementia, given the central role that the system plays in   
governing executive functions and mood regulation. One subtype of DEP coined as “vascular 
DEP” is characterized by deficits in executive functioning, presence of WMHs, and poor 
antidepressant treatment response (Alexopoulos et al., 1997). The vascular DEP subtype, 
however, has been explored primarily in the context of non-amnestic MCI. Patients presenting 
with amnestic MCI have typically been excluded in most studies of vascular DEP to maintain 
internal validity.  Therefore, patients enrolled in these studies may not represent the full range 
of patients with DEP-CI (G. Alexopoulos et al., 2005; Alexopoulos, 2005; Alexopoulos et al., 
2000). There is also an established association between vascular disease and the development 
of vascular dementia, with major depressive disorder (MDD) occurring in approximately 20% of 
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patients with vascular dementia (Newman, 1999). Thus, vascular DEP might fall on a continuum 
that would include vascular disease, vascular MDD itself, post-stroke DEP, and vascular 
dementia.  Indeed, Steffens and colleagues have reported in a case study of an elderly woman 
the progression of subcortical ischemic disease from vascular DEP to vascular dementia 
(Steffens, Taylor, & Krishnan, 2003).   
 
Cortical Thickness and Depression 
In terms of cortical thickness, reductions in the left insular region (Mak, Colloby, 
Thomas, & O'Brien, 2016)  and anterior cingulate cortex have been reported in late life DEP 
patients (M. Li et al., 2014). Thinner left anterior cingulate cortex and medial superior frontal 
gyrus volumes are seen in patients with type 2 diabetes and DEP compared to healthy subjects 
(Ajilore et al., 2010). Lim et al. (2012) found patients with late-onset DEP had decreased cortical 
thickness in the rostral anterior cingulate cortex, medial orbitofrontal cortex, dorsolateral 
prefrontal cortex, superior and middle temporal cortex, and posterior cingulate cortex when 
compared to age-matched healthy controls. As in MCI, cortical thinning in patients with late-
onset DEP was linked with reduced cognitive functioning. Performance on delayed verbal 
memory tests was positively correlated with cortical thickness in the left superior temporal, 
precuneus, inferior temporal, and insula for patients with late-onset DEP. Moreover, inhibition 
and set-shifting test scores (facets of executive functioning) were positively correlated with 
right anterior cingulate cortex, rostral middle frontal gyrus, and left insula thicknesses (Lim et 
al., 2012). Other clinical trials have reported no cortical thickness differences between late life 
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DEP and healthy controls, though these studies included patients with either current or 
previous DEP episodes (Colloby et al., 2011; Koolschijn et al., 2010). Not all clinical trials report 
cortical thinning. Indeed, regional increases in cortical thickness have been reported in middle-
aged patients with untreated, first-episode DEP. These include the temporal pole, caudal 
anterior cingulate cortex, posterior cingulate cortex (van Eijndhoven et al., 2013), medial 
orbitofrontal gyrus, pars opercularis, rostral middle frontal gyrus, and supramarginal gyrus (Qiu 
et al., 2014). In the same population, however, thinner medial orbitofrontal cortex has also 
been reported (van Eijndhoven et al., 2013).  
In terms of cortical thickness and DEP severity, results are similarly mixed, with multiple 
studies reporting increased thinning of the frontal and temporal lobes in patients with greater 
DEP symptoms, and others reporting no such association. Notably, there is evidence of a 
positive relationship between both posterior cingulate cortex (Truong et al., 2013) and rostral 
middle frontal gyrus thickness and DEP severity (Qiu et al., 2014). In samples of community-
dwelling older adults with a range of DEP symptoms, greater DEP severity was associated with 
greater cortical thickness in the right isthmus cingulate and left precuneus (Szymkowicz et al., 
2016). 
 
Cortical Thickness Impacts Treatment Outcome 
Cortical thickness has been examined as a possible predictor of treatment outcome. In a 
12-week treatment trial using the SSRI sertraline for patients with late-life DEP, non-remitters 
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had thinner frontal poles at baseline than remitters (Sheline et al., 2012). Another longitudinal 
trial of middle-aged adults found patients with DEP had thinner frontal and temporal lobe 
cortices compared to healthy controls, including the orbitofrontal cortex, superior temporal 
lobe and insular cortex (Jarnum et al., 2011). Additionally, 6-month non-remitters had thinner 
posterior cingulate cortices than remitters. A more recent study also provided evidence for an 
association between cortical thickness of frontal, temporal, and limbic structures and treatment 
remission. In this antidepressant trial of patients aged 18-65 with treatment-resistant DEP, 
thicker baseline right caudal anterior cingulate cortex was associated with greater symptom 
improvement. Patients who achieved sustained 6-month remission following open, intensive 
antidepressant treatment had increased hippocampal volume and increased cortical thickness 
in the rostral middle frontal gyrus, orbitofrontal cortex, and inferior temporal gyrus over time. 
Non-remitters had decreased volume and thickness in the same areas at follow-up (Phillips, 
Batten, Tremblay, Aldosary, & Blier, 2015). Given the naturalistic treatment approach of these 
latter two studies, it is not possible to ascribe these effects to a specific class of medication. 
Cortical thickness predicts the effectiveness of psychotherapy for late life DEP as well. Problem-
solving therapy non-responders demonstrated thinner bilateral posterior cingulate cortices and 
parahippocampal cortices, left precuneus, cuneus, and insular cortices, and the right medial 
orbitofrontal and lateral occipital cortices relative to responders (Mackin et al., 2013).  
In sum, reduced cortical thickness is related to reduced efficacy of interventions for 
depression. The affected sub-regions within the frontal, temporal, and limbic areas vary across 
trials. Results of these studies indicate that longitudinal structural grey matter changes depend 
on the success of antidepressant treatment, and initial cortical thickness at treatment onset 
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may predict outcome. Critically, successful treatment appears to reverse atrophy in fronto-
limbic areas. This holds particular relevance for DEP-CI, where cortical thinning in these areas is 
connected to more rapid dementia onset. The mechanism responsible for the reversal in grey 
matter loss potentially involves reduction in inflammation, activation of neuroprotective 
cellular mechanisms (Hunsberger, Austin, Henter, & Chen, 2009), stabilization of the 
hypothalamic-pituitary (HPA) axis (Anacker, Zunszain, Carvalho, & Pariante, 2011), or a 
combination of these or additional factors. 
The inconsistency in reported regional cortical thickness alterations amongst DEP 
patients stems from equally variable methodological factors, including irregular a priori 
selection of regions of interest (ROI), ROI vs whole brain analyses, distinct cortical 
reconstruction techniques, multiple atlas parcellations, and inconsistent corrections for 
multiple comparisons. Patient demographics such as age vary considerably across studies, as 
does method of treatment, how treatment outcome is evaluated (response or remission). 
Beyond the array of reported regions affected in DEP patients, the directionality of cortical 
alterations also remains unclear. While the majority of treatment outcome studies report 
cortical thinning as an indicator of worse prognosis, this directionality is less consistently 
observed when comparing DEP patients to healthy controls and in correlational analyses of 
cortical thickness with depression severity, as multiple studies have reported a positive 
relationship between cortical thickness and DEP severity. 
A major anatomical commonality shared between DEP and aMCI is atrophy of the 
hippocampus. This limbic system structure plays a critical role in the formation of memories 
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and regulation of the HPA axis. A meta-analysis of 35 studies investigating hippocampal volume 
in late life DEP found significantly smaller hippocampal volume than in controls. In addition, 
late-onset DEP had greater hippocampal volume loss than patients with early-onset DEP 
(Geerlings & Gerritsen, 2017). Smaller baseline hippocampal volume is associated with an 
increase in DEP symptoms over an 8 year period, whereas larger hippocampal volume is 
associated with a decrease in symptoms over the same period (Buddeke et al., 2017). Reduced 
hippocampal volume has been found to predict antidepressant treatment nonresponse in late 
life DEP (Sheline et al., 2012) and greater risk of conversion to AD in MCI (Chung et al., 2015; 
Jack et al., 2004). Hippocampal atrophy is at least partially caused by exposure to 
glucocorticoids released in response to chronic stress. Indeed, higher cortisol levels are 
associated with reduced neurogenesis and smaller hippocampal volume in LLD (Geerlings & 
Gerritsen, 2017). Atrophy and reduced neurogenesis by themselves do not result in a 
depressive disorder, however, they do appear to mediate the effects of 
antidepressants(Samuels & Hen, 2011). 
 
Interim Summary 
DEP and CI share etiological risk factors, anatomical underpinnings, and interact to 
produce deleterious treatment outcomes. Both DEP and CI exhibit altered patterns of WMHs 
and cortical thickness compared to healthy individuals. These structural changes complicate the 
course of depression treatment. Research focused on CI tends to exclude DEP by excluding 
affective disorders (Avila et al., 2015; Defrancesco et al., 2014; Devanand et al., 2000), and 
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research on late-life DEP tends to exclude memory disorders and CI (Sheline et al., 2012) by 
using a cutoff score for the Mini-Mental State Examination (MMSE) (Alexopoulos, Kiosses, 
Murphy, & Heo, 2004; Manning et al., 2015; Pimontel et al., 2013; Reinlieb et al., 2014; Yuen et 
al., 2014). This creates a bias against the study of comorbid DEP and CI in older adults. Since 
there is a clear, commonly occurring association between DEP and CI (Geda et al., 2008; Panza 
et al., 2010; Rozzini et al., 2008), it is important to learn more about the characteristics of 
patients presenting with both conditions. To date, no study has examined cortical thickness or 
WMH patterns of patients with DEP-CI, nor their impact on treatment response.  
 
Aims and Hypotheses 
To clarify the clinical and radiological correlates of patients with DEP-CI, we examined 
differences between EMCI and LMCI in a sample of patients with DEP and CI participating in an 
antidepressant treatment trial. We also examined predictors of acute treatment outcome. We 
hypothesize the following: 
Aim 1: To compare MCI subtypes cross-sectionally on clinical and neuropsychological 
characteristics. 
H1: It is hypothesized that there will be worse global cognitive functioning (Alzheimer’s 
Disease Assessment Scale-Cognitive, Mini Mental Status Examination) in LMCI than 
EMCI. 
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H2: It is hypothesized that temporal lobe volume will be reduced in LMCI compared to 
EMCI 
H3: It is hypothesized that cortical thickness will be reduced in LMCI compared to EMCI. 
Aim 2: To examine predictors of acute antidepressant remission. 
H1: It is hypothesized that cortical thickness will be reduced in non-remitters compared 
to remitters. 
H2: It is hypothesized that WMH volume will be greater in non-remitters compared to 
remitters. 
Exploratory Hypotheses: 
H1: It is hypothesized that non-responders will have reduced cortical thickness and 
greater WMH volume than responders. 
H2: It is hypothesized that LMCI patients will have greater rates of nonresponse and 
nonremission than EMCI patients. 
H3: It is hypothesized that ADAS-Cog scores will be significantly correlated with cortical 
thickness 
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METHOD 
The full DOTCODE (Donepezil Treatment of Older Adults with Cognitive Impairment) 
study procedures have been described elsewhere (Pelton et al., 2014). The targeted sample size 
was 80 patients with DEP and CI based on power analysis for the clinical trial. Patients were 
recruited from two sites. The recruitment process at the New York State Psychiatric 
Institute/Columbia University Medical Center obtained patients from the Late Life Depression 
Clinic, Memory Disorders Center, the Behavior Neurologist’s practice group, and from 
newspaper advertising. The recruitment process at the Duke University Medical Center 
obtained patients from the caseload of investigators, the late-life mood disorders programs, the 
Center for the Study of Aging, community advertisements, and referral by psychiatric, primary 
care, public health (inner city) and geriatric medicine clinics associated with Duke University. 
Overall, 160 patients were screened. 81 were excluded; of these 67 did not meet study criteria 
and 14 withdrew consent. 79 patients signed informed consent forms at screening and were 
enrolled in the study.  Of these 79 patients, 39 participated at the New York State Psychiatric 
Institute/Columbia University Medical Center site and 40 participated at the Duke University 
Medical Center. 
Inclusion Criteria 
1. Male or female, age 55-95 years old, with minimum 8 years of education who meet 
criteria for both DEP and CI (assessed by physician evaluation). 
2. Study Criteria for “DEP” (assessed by interview by psychiatrist for DSM-IV items, 
Hamilton Depression Rating Scale, Structured Clinical Interview for DSM-IV [SCID] Mood 
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Disorders Section, and neuropsychological testing by nurse/social worker/research 
coordinator): 
a. Patients who meet DSM-IV symptom criteria for Major DEP or Dysthymia for a 
minimum of 6 months (2-year duration DSM-IV TR criterion not required for 
dysthymic disorder in this study). 
b. 24-item Hamilton Depression Rating Scale (HDRS) ≥14. 
3. Study Criteria for “CI” (assessed by trained research coordinator): 
a. Subjective memory or other cognitive complaints. 
b. Score < 11 on the Logical Memory II (Delayed Paragraph Recall, Paragraph A) test 
from the Wechsler Memory Scale – Revised (WMS-R)(Wechsler, 2009) OR score 
1.5 SD or more below norms on the Free and Cued Selective Reminding Test-
Immediate or Delayed Recall (FCSRT)(Buschke, 1984). 
4. Folstein MMSE (Folstein, Folstein, & McHugh, 1975) score ≥ 21 out of 30 to rule out 
moderate to severe impairment (assessed by trained research coordinator). 
5. Clinical Dementia Rating (CDR)(Morris, 1993) by study physician of 0.5 on the memory 
item, and global rating of 0.5 indicating questionable dementia (assessed by evaluating 
physician). 
6. Willing and capable of giving informed consent (assessed by evaluating physician). 
Exclusion Criteria 
1. Meets criteria for dementia (DSM-IV) or probable AD (NINCDS-ADRDA criteria) (assessed 
by evaluating physician). 
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2. Meets DSM IV TR criteria for (assessed by SCID-I administration by trained research 
coordinator or research social worker): 
a. schizophrenia, schizoaffective disorder, psychotic DEP or other psychosis, or 
bipolar I disorder 
b. alcohol or substance dependence or abuse (current or within past 6 months) 
3. Active suicidal ideation or suicidal attempt in the last 6 months (assessed by interview 
by psychiatrist). 
4. Clinical stroke with residual neurological deficits (assessed by evaluating physician). 
5. Use of medications that (assessed by evaluating physician and medical history): 
a.) Would interact in a clinically significant manner with the study medications: 
warfarin or monoamine oxidase inhibitors (MAOIs) 
b.) are known to have a negative impact on cognition: benzodiazepines in 
lorazepam equivalents ≥ 2 mg daily, narcotics, or anticholinergics. (N.B. 
Medications that may be associated with CI but are rarely considered the likely 
etiology, e.g, theophylline, nifedipine, Beta blockers, were not excluded.) 
Patients were not washed off of these medications and were automatically 
ineligible to participate. 
6. Presence of any of the following disorders: a) central nervous system infection, with 
cerebral spinal fluid evidence of meningitis, encephalitis, or other infectious process; b) 
Post-traumatic dementia, defined as dementia with a clear temporal relationship to a 
severe head injury where consciousness was lost; c) Huntington’s disease; d) Multiple 
sclerosis; e) Parkinson’s disease; f) Other neurologic disorders with focal signs, e.g., 
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amyotrophic lateral sclerosis; g) Mental retardation (assessed by evaluating physician 
and medical history). 
7. Any acute, severe unstable medical condition. For cancer, acutely ill patients (including 
those with metastases) are excluded, but past history of successfully treated cancer did 
not result in exclusion (assessed by evaluating physician and medical history). 
8. Contra-indication to magnetic resonance imaging (MRI) scan: pacemaker, metal 
implants following surgery, any other contraindication to MRI (e.g., ferromagnetic 
aneurysm clips, heart valves). For patients with possible claustrophobia, they could do 
the MRI with adjunct lorazepam 0.5 mg to reduce anxiety. Patients who could not do 
the MRI scan were still eligible for the clinical trial, i.e., MRI is optional (assessed by 
evaluating physician). 
9. Hypertension (blood pressure (BP) ≥ 140/90 mm Hg) at the evaluation visit. However, if 
the patient's primary care physician was comfortable with the patient's BP being above 
140/90, but below 150/100 mm Hg, the patient could be included in the protocol 
(assessed by blood pressure screening). 
10. Patients currently on an effective antidepressant medication. No patient was washed 
out of an effective antidepressant (assessed by evaluating physician). 
11. Patients with QTc N 460 ms on baseline EKG were excluded. Patients with a baseline 
QTc N 460 ms had the option of receiving venlafaxine ER as the initial treatment. All 
absolute contraindications listed in the package inserts for citalopram, venlafaxine and 
donepezil were followed (assessed by electrocardiogram [EKG]). 
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Antidepressant Treatment 
Patients already receiving antidepressant treatment underwent a medication washout 
lasting 0-14 days, determined by clinician’s judgement. All patients received open 
antidepressant treatment with either citalopram or venlafaxine for the first 8 weeks. During the 
first week, all patients on citalopram began with 10mg/day. This increased to 20mg/day during 
the second week, and again to a maximum of 40mg/day at week 4 for patients under 60. 
Patients over 60 received a maximum dose of 20mg/day because of the Food and Drug 
Administration warning about prolonged QTc interval with higher doses of citalopram in this 
age group. All patients on venlafaxine began with 37.5mg/day. This increased weekly, as 
tolerated and based on clinical response, to a maximum of 225mg/day at the fifth visit. At week 
8, medication response was evaluated. Patients were classified as remitters if they obtained a 
week 8 score of 0-7 on the HDRS, or as non-remitters if they obtained a week 8 score on the 
HDRS of 8+. Patients were classified as responders if they achieved a 50% or greater reduction 
from baseline HDRS scores at week 8, or were classified as non-responders if they achieved less 
than 50% reduction from baseline HDRS.  
Measures 
 At week 0, participants completed an MRI scan, clinical evaluation and a 
neuropsychological battery. At week 8, the clinical evaluation and neuropsychological battery 
were repeated. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G)(Linn, Linn, & Gurel, 
1968) was administered to document medical burden in the major organ systems. The 
University of Pennsylvania Smell Identification Test (UPSIT, scratch and sniff 40- item multiple-
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choice test)(Doty, Shaman, & Dann, 1984) was the primary odor identification measure. The 
Functional Activities Questionnaire (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982) was given 
to both patients and informants to evaluate instrumental and social/cognitive activities of daily 
living. A neuropsychological test battery was used to tap into deficits in both DEP and CI. The 
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog, 13-item version, max score 85) 
(Mohs et al., 1997) was administered to determine cognitive functioning across multiple 
domains. Non-verbal learning and memory were assessed using the Wechsler Memory Scale III 
(WMS-III) Visual Reproduction subtest (Wechsler, 1997c). Visuospatial skills were measured 
using the Wechsler Adult Intelligence Scale-III (WAIS-III) Block Design subtest (Wechsler, 
1997a). The 15-item Boston Naming Test(Goodglass, Kaplan, & Barresi, 2000) (BNT, total 
spontaneous responses) was used to assess confrontation naming ability. CFL Letter and Animal 
naming (60-second trials) were used to evaluate verbal fluency (Steinberg, Bieliauskas, Smith, & 
Ivnik, 2005). Trails A served as an estimate of attention and Trails B was used to measure set-
shifting ability (Battery, 1944). The Stroop Color-Word Interference Test was used to evaluate 
inhibition/set-shifting ability. WAIS-III Digit Symbol (Wechsler, 1997b) measured processing 
speed. Apolipoprotein E genotype was determined through the laboratory of the Human 
Genetics Resources Core (HGRC) at Columbia University using blood samples. 
CI Subtyping 
Patients were classified as LMCI if they scored ≥1.5 SD below norms on immediate or 
delayed recall on the SRT, or WMS-R Logical Memory II. All patients who met minimum WMS-R 
Logical Memory II inclusion criteria (score of ≤ 11 on delayed recall) but did not reach a 1.5 SD 
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threshold below norms on either WMS-R Logical Memory II or SRT immediate or delayed recall 
were classified as EMCI. 
Anatomical Data Acquisition 
MRI scans were completed at baseline. Images were acquired on a GE Signa 3 Tesla 
whole body scanner with the following sequences: 1) 3-Plane localizer repetition time (TR) = 
23.4 ms, echo time (TE) = 1.7 ms, flip angle = 30°, bandwidth = 31.3 MHz, field of view (FOV) = 
24 × 24 cm, thickness = 5.0 mm, Spacing = 1.5 mm, 9 slices per volume (3 axials, 3 sagittals, 3 
coronals), matrix 256 × 128, 2) 3D SPGR anatomical sequence TI 500 ms, TR 5 ms, TE minimum 
(1.3 ms), flip angle 11°, bandwidth 31.25 MHz, FOV 26 × 26, slice thickness 1.1 mm, spacing 0.0, 
128 slices per volume, 1 NEX images × 2 (acquisitions averaged off line), matrix 256 × 256 
coronal oblique orientation, aligned to the long axis of the hippocampus, and 3) T2 fluid-
attenuated inversion recovery (FLAIR): 2D IR axial images, TR = 10,000 msec, TE = 122 msec, TI = 
2000 msec, FOV = 24, matrix = 320 × 256, NEX = 1, slice thickness = 5 mm, 31 slices.  
Regions of interest (ROIs) in the temporal lobe and limbic system, chosen a priori, were 
based on published studies identifying regions predicting increased risk of dementia in MCI. A 
single trained, experienced technician blind to treatment outcome drew the hippocampus, 
parahippocampal gyrus, and entorhinal cortex ROIs using atlas-based approaches on MRI scans.  
This technician established high interrater reliability with other trained expert raters (Intraclass 
Correlation Coefficient [ICC]=.90-.96) and high intrarater reliability over one year (ICC=.97-.99) 
(Devanand et al., 2007). 
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Hyperintensities on axial T2 FLAIR images were rated using the Fazekas-modified Coffey 
Rating Scale (Fazekas, Chawluk, Alavi, Hurtig, & Zimmerman, 1987), a qualitative rating of lesion 
severity. Deep white matter hyperintensities (DWMH) are scored as 0 (absent), 1 (punctate 
foci), 2 (beginning confluence of foci), and 3 (large confluent areas); subcortical gray matter 
hyperintensities in the basal ganglia (SCG) are scored as 0 (absent), 1 (punctate), 2 
(multipunctate), and 3 (diffuse); periventricular hyperintensities (PVH) are scored as 0 (absent), 
1 (caps), 2 (smooth halo), and 3 (irregular and extending into the deep white matter). Ratings 
were provided by a radiologist trained on this scale. Patients were classified as having ‘low 
DWMH’ if they had ratings of 0 or 1 on the Fazekas-modified Coffey Rating Scale and classified 
as having ‘high DWMH’ if they had ratings of 2 or 3. Patients were classified as having ‘low PVH’ 
if they had ratings of 0 or 1 and classified as having ‘high PVH’ if they had ratings of 2 or 3.  
Additionally, T2 FLAIR lesion volume was measured on a parallel, semi-automated 
version of this scale (Figure 1) using MRIcro, a program for visualizing medical images.  
(http://www.sph.sc.edu/comd/rorden/mricro) (Rorden & Brett, 2000). This procedure begins 
with the application of a global intensity filter to the T2 volume, which is adjusted for each 
volume to select voxels above a threshold specified for each volume. This allows for 
distinguishing between hyperintense regions and and non-hyperintense surrounding tissues. 
Next, raters manually trace the outline of suspected hyperintensities in the deep white, 
periventricular, and subcortical grey regions separately for each slice in the volume to 
distinguish hyperintensities from ordinarily occurring white voxels (e.g., skull, cranial nerves, 
choroid plexus). Lastly, areas of mutual overlap between the intensity filter and the tracings for 
each region are extracted, with overall volume computed as the sum of all highlighted voxels 
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across the regions of interest.  Our group has published extensively using these methods 
(Pimontel et al., 2013; Sneed et al., 2011) and raters using this semi-automated approach have 
achieved excellent interrater reliability (ICC=.98).  
Cortical thickness was extracted using FreeSurfer version 6.0, an automated brain 
segmentation program which constructs boundaries between white matter, cortical grey 
matter, and pial surface (Dale, Fischl, & Sereno, 1999). FreeSurfer is a free software program 
that can downloaded (http://surfer.nmr.mgh.harvard.edu). First, T1-weighted structural images 
were corrected for motion errors and underwent non-uniform intensity normalization (Reuter, 
Rosas, & Fischl, 2010). Non-brain tissue was removed using a hybrid watershed/surface 
deformation procedure (Segonne et al., 2004). Next, an affine transformation registered the 
original volumes to Talairach coordinate space and the MNI305 atlas. Next, the procedure 
involved segmentation of the subcortical white matter and deep gray matter volumetric 
structures (including hippocampus, amygdala, caudate, putamen, ventricles) (Fischl et al., 2002; 
Fischl, Salat, et al., 2004) intensity normalization (Sled, Zijdenbos, & Evans, 1998), tessellation of 
the gray matter white matter boundary, automated topology correction (Fischl, Liu, & Dale, 
2001; Segonne et al., 2004), and surface deformation following intensity gradients to optimally 
place the gray/white and gray/cerebrospinal fluid borders at the location where the greatest 
shift in intensity defines the transition to the other tissue class (Dale et al., 1999; Dale & Sereno, 
1993; Fischl & Dale, 2000). Once the cortical models were complete, a number of deformable 
procedures were performed for further data processing and analysis including surface inflation 
(Fischl, Sereno, & Dale, 1999), registration to a spherical atlas which is based on individual 
cortical folding patterns to match cortical geometry across subjects (Fischl, Sereno, Tootell, & 
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Dale, 1999), parcellation of the cerebral cortex into units with respect to gyral and sulcal 
structure (Desikan et al., 2006; Fischl, van der Kouwe, et al., 2004), and creation of a variety of 
surface based data including maps of curvature and sulcal depth. This method used both 
intensity and continuity information from the entire three-dimensional magnetic resonance 
volume in segmentation and deformation procedures to produce representations of cortical 
thickness, calculated as the closest distance from the gray/white boundary to the gray/CSF 
boundary at each vertex on the tessellated surface (Fischl & Dale, 2000). The maps were 
created using spatial intensity gradients across tissue classes and are therefore not simply 
reliant on absolute signal intensity. The maps produced are not restricted to the voxel 
resolution of the original data thus are capable of detecting submillimeter differences between 
groups. Procedures for the measurement of cortical thickness have been validated against 
histological analysis (Rosas et al., 2002) and manual measurements (Kuperberg et al., 2003; 
Salat et al., 2004). Freesurfer morphometric procedures have been demonstrated to show good 
test-retest reliability across scanner manufacturers and across field strengths (Han et al., 2006; 
Reuter, Schmansky, Rosas, & Fischl, 2012).  
Statistical analyses 
Means and standard deviations were computed to describe continuous variables, while 
frequencies and percentages were used for categorical variables. All analysis of covariance 
(ANCOVA), logistic regression, and baseline demographic analyses were performed at p<0.05 
for inference using the Statistical Package for the Social Sciences version 23 software (IBM Corp, 
2012). The chi square test for independence and the independent samples t-test were used to 
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evaluate differences between sites on demographic characteristics of age, sex, race, and 
education. ANCOVA was used to compare EMCI and LMCI groups on continuous clinical, 
neuropsychological, and anatomical variables. Logistic regression was used for nominal 
anatomical variables. All ANCOVA and logistic regression models included age, sex, HDRS, and 
years of education as covariates.  
Within surface-based morphometry, there are two primary approaches to evaluating 
cortical thickness – vertex-wise analysis and ROI-based analysis. Vertex-wise analyses evaluates 
cortical thinning according to clusters, which are sets of spatially contiguous vertices that are 
above a given threshold, whereas ROI-based analysis uses averaged cortical thickness values 
within a predetermined, gyral-based atlas. Averaging the cortical thicknesses of all vertices 
within an ROI can obstruct detection of group differences because the part of the region 
containing features of interest is averaged out with parts of the region where no group 
differences exist. Vertex-wise analysis has high sensitivity, and enable detection of cortical 
thickness differences that do not conform to the boundaries of predefined cortical parcellations 
(Woo, Krishnan, & Wager, 2014). Additionally, it allows for whole-brain exploratory data 
analysis without any a priori constraints and is therefore not restricted to limited selections of 
ROIs as search spaces for cortical thinning. Given these advantages, the inconsistency of ROI 
selection in the DEP and CI literatures, and the absence of any previous studies on cortical 
thickness for comorbid DEP-CI, vertex-wise analysis was chosen to evaluate the current 
hypotheses. One notable limitation of vertex-wise analysis is low spatial specificity when 
clusters are large. This is because the cluster-level p-value does not determine statistical 
significance of thickness values at a specific location within a cluster. Instead, the cluster-level 
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p-value is the probability of obtaining a cluster of the determined size if the null hypothesis 
were true. 
During the cortical reconstruction process, the cortical surface is modeled as a mesh of 
triangles (occurring within the tessellation step). The meeting point of multiple triangles along 
the surface forms a vertex. Cortical thickness is computed as the distance between the white 
matter surface and pial surface at each vertex along the cortex. The thickness maps for all 
subjects were converted to the common atlas space (Fischl, Sereno, & Dale, 1999; Fischl, 
Sereno, Tootell, et al., 1999) and smoothed by applying a 2D Gaussian kernel of 10mm. A series 
of whole brain, vertex-wise analyses were conducted using general linear models to compare 
cortical thickness of remitters vs non-remitters, responders vs non-responders, and EMCI vs 
LMCI. Correlation models were also conducted to evaluate the relationship between cortical 
thickness and both baseline HDRS and ADAS-Cog. Site, sex, age, baseline HDRS, MCI subtype, 
and years of education were entered as covariates. Because all the subject’s cortical thickness 
maps were aligned to the common surface template, intracranial volume was not used as a 
covariate. The initial vertex-level primary threshold defined clusters by retaining groups of 
suprathreshold vertices and was set at p<0.001. Group differences in clusters were evaluated 
by a second, cluster-level extent threshold of p<0.05. These values are recommended as they 
balance the unique strengths and limitations of cluster-level extent thresholding (Woo et al., 
2014). A monte carlo null-z procedure was used to correct for multiple comparisons. Cluster 
location was reported based off the vertex of maximum value’s location within the Desikan-
Killany atlas (Klein & Tourville, 2012)(Figure 4). 
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Binary logistic regression was used to evaluate the effects of WMH and MCI subtype on 
treatment outcome. Separate models were used for treatment remission and treatment 
response as dependent variables. Site, sex, age, education, baseline HDRS, DWMH Load, PVH 
Load, and MCI type were specified as independent variables. Models were fit using forward, 
stepwise selection with entry testing for each independent variable based on the statistical 
significance of the score statistic and removal testing for each variable based on the difference 
in -2 Log Likelihoods (-2LL) from the previous model.  
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RESULTS 
Aim 1: To compare MCI subtypes cross-sectionally on clinical and neuropsychological 
characteristics. 
Descriptive statistics for demographic characteristics, clinical surveys, 
neuropsychological assessments, and brain tissue volumes are presented in Tables 1-6. The 
average age was 68.9 (SD = 9.0) years, with 51.9% of the sample being male and 48.1% female 
(Table 1). There was no difference between the two sites in age [t(77)=-0.5, p=.62], sex [χ2(2, 
n=79)=0.1, p=.81], or education [t(77)=-0.5, p=.60]. In terms of marital status, 35.4% were single 
or never married, 24.1% were divorced or separated, 29.1% were married or living with a 
partner, and 11.4% were widowed. 36.7% were currently employed, 46.8% were retired, and 
16.5% were unemployed or disabled. All patients were living at home. 
 The mean ADAS-Cog score was 14.3 and the mean 24-item HDRS score was 23.0. Many 
patients had a family history of depression (50.6%), dementia (45.6%), or Alzheimer’s disease 
(16.5%). On the CIRS-G, patients had a mean score of 7.4, with 10.1% reporting current mild or 
past significant vascular problems, and 25.3% reporting moderate disability or comorbidity as a 
result of their vascular illness. The mean FAQ – Patient Score was 4.0 and the mean FAQ – 
Informant Score was 3.1, indicating that patients were generally able to complete instrumental 
activities of daily living with minimal difficulty and were not consistently dependent upon 
others. 29.5% of patients possessed a homozygous or heterozygous genotype for the ApoE4 
allele. 
MRI Anatomical Characteristics 
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55 patients completed MRIs. Patients who did not complete an MRI scan were 
significantly more likely to be divorced/separated and or widowed than patients who did 
complete an MRI scan [χ2(2, n=79)=9.7, p=.021], though were otherwise comparable on 
baseline demographics and clinical characteristics (Table 2). Of the MRI patients, 24 were 
classified as EMCI and 31 were LMCI. Patients possessed varying severities of DWMH:  5.5% 
were rated as 3, 10.9% as 2, 60.0% as 1, and 23.6% were rated as having none. PVH were 
absent in only 7.3% of the sample, with 47.3% having a rating of 1, 30.9% had a rating of 2, and 
14.5% had a rating of 3. Subcortical grey matter hyperintensities occurred in a single patient. 
For hyperintensity volumes obtained using the semi-automated method, patients had means of 
5.6, 28.5, and 34.1 cubic centimeters for deep white, periventricular, and total hyperintensity 
volumes respectively. 
 
Aim 1: H1: It is hypothesized that there will be worse global cognitive functioning (Alzheimer’s 
Disease Assessment Scale-Cognitive, Mini Mental Status Examination) in LMCI than EMCI. 
 In the full sample, 39 patients met criteria for EMCI and 40 met criteria for LMCI.  Both 
subtypes were comparable in terms of demographic features including age, sex, education, 
race, marital status, and employment status (Table 1). No differences between the subtypes 
were found for family histories of depression or dementia, prevalence of vascular problems, 
baseline depression severity, or ApoE genotype. There were also no differences between the 
groups on self-reported or informant-reported instrumental activities of daily living. In terms of 
cognitive functioning, there was a statistically significant difference between groups, such that 
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the EMCI group had superior performance on ADAS-Cog (Figure 5), MMSE, Block Design, Digit 
Symbol, Animal fluency, Visual Reproduction II, and UPSIT. No differences between the groups 
were found for Digit Symbol, Letter fluency, Visual Reproduction I, Trails A, Trails B, Stroop, or 
Boston Naming Test (Table 5).  
 
Aim 1: H2: It is hypothesized that temporal lobe volume will be reduced in LMCI compared to 
EMCI 
Of the 55 patients with MRI scans, 24 Patients were classified as EMCI and 31 were 
classified as LMCI. At baseline, there were no significant differences between the MCI groups 
on demographic and clinical characteristics including age, sex, years of education, or baseline 
depressive severity. The LMCI group had statistically significantly less volume in the right 
hippocampus than the EMCI group (Table 6). All other regions had comparable volumes in EMCI 
and LMCI, including the bilateral entorhinal cortex, bilateral parahippocampal gyrus, left 
hippocampus, and total hippocampus (Figure 6). For WMH, there were no statistically 
significant group differences in lesion severity for DWMH, PVH, or SCG using the Fazekas-
modified Coffey Rating Scale. In terms of lesion volume, there were also no statistically 
significant differences between the LMCI and EMCI groups.  
 
Aim 1: H3: It is hypothesized that cortical thickness will be reduced in LMCI compared to EMCI 
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The EMCI group had statistically significantly greater right hemisphere medial 
orbitofrontal cortex thickness than the LCMI group (cluster size=139.42mm, cluster-wise 
p=.0438), after covarying for site, sex, age, baseline HDRS, MCI type, and years of education, 
and correcting for multiple comparisons using the monte carlo null-z procedure (Figure 7). 
 
Aim 2: To examine predictors of acute antidepressant remission. 
Of the patients with MRI scans, 15 were classified as remitters (week 8 HDRS score of 7 
or less) and 40 as non-remitters (week 8 HDRS score of greater than 7). 35 were classified as 
responders (50% or greater reduction in HDRS from week 0 to week 8) and 20 as non-
responders (less than 50% reduction in HDRS from week 0 to week 8). At Baseline, there were 
no significant differences between remitters and non-remitters on demographic or clinical 
characteristics (Table 3). Non-responders were significantly older (t=2.1, p=.037) and had 
significantly lower baseline HDRS (t=-3.2, p=.003) than responders (Table 4). 
 
Aim 2: H1: It is hypothesized that cortical thickness will be reduced in non-remitters compared to 
remitters. 
Remitters had statistically significantly greater left hemisphere medial orbitofrontal 
cortex (cluster size=160.55mm, cluster-wise p=.0269) and right hemisphere superior frontal 
gyrus (cluster size=152.51, cluster-wise p=.0315) thickness than non-remitters, after covarying 
for site, sex, age, baseline HDRS, MCI type, and years of education, and correcting for multiple 
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comparisons using the monte carlo null-z procedure (Table 7; Figure 8). Other clusters in the 
left hemisphere middle temporal gyrus, parahippocampal gyrus, rostral middle frontal 
gyrus, and pars orbitalis were also thicker in remitters (p<.001), though failed to survive error 
correction. There was no interaction between MCI subtype and remission status in relation to 
cortical thickness.  
 
Aim 2: H2: It is hypothesized that WMH volume will be greater in non-remitters compared to 
remitters. 
In step 0 of the logistic regression model of HDRS remission, no predicters were 
entered, resulting in a ‘null model’ with the intercept only. The model correctly predicted 72.7% 
of non-remitter cases (β=-.981, SE=.303, p=.001, odds ratio=.375). In step 1 of the model, 
DWMH load was entered with an overall -2 LL model fit of 60.535 (β=.223, SE=.671, p=.739, 
odds ratio=1.250). Patients classified as high DWMH were significantly more likely to remit 
following antidepressant treatment compared to patients classified as having low DWMH 
(estimate=-1.504, SE=.760, p=.048, odds ratio=.222, 95% CI=.050 – .986). Removing DWMH load 
would result in a significant worsening of model fit (-2LL change=3.920, p=.048). The model 
correctly predicted 90.0% of non-remitter cases and 33.3% of remitter cases (74.5% overall). In 
step 2, the final step of the model (Table 8), DWMH load remained included and age was 
added, resulting in an overall -2LL model fit of 56.254 (β=6.837, SE=3.580, p=.056, odds 
ratio=931.853). Patients classified as high DWMH remained more likely to remit following 
antidepressant treatment compared to patients classified as having low DWMH (estimate=-
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2.141, SE=.903, p=.018, odds ratio=.117, 95% CI=.020 – .690). Removing DWMH rating would 
result in a significant worsening of model fit (-2LL change=6.245, p=.012). Greater age tended to 
be associated with lower chance of remission, though was not statistically significantly 
associated with remission status (estimate=-.091, SE=.048, p=.059, odds ratio=.913, 95% 
CI=.831-1.003). However, removing age would result in a significant worsening of model fit and 
thus was retained (-2LL change=4.281, p=.012). The model correctly predicted 97.5% of non-
remitter cases and 26.7% of remitter cases (78.2% overall). MCI type, PVH load, sex, site, years 
of education, and baseline HDRS were not significantly associated with remission in any steps of 
the model. 
 
Exploratory Hypotheses: H1: It is hypothesized that non-responders will have reduced cortical 
thickness and greater WMH volume than responders. 
In step 0 of the logistic regression model of HDRS response, no predicters were entered, 
resulting in a ‘null model’ with the intercept only. The model correctly predicted 63.6% of cases 
as responders (β=.560, SE=.280, p=.046, odds ratio=1.750). In step 1, the final step of the model 
(Table 9), baseline HDRS was entered with an overall -2 LL model fit of 62.063 (β=-3.930, 
SE=1.614, p=.015, odds ratio=.020). Greater baseline HDRS was associated with significantly 
increased likelihood of response (estimate=.200, p=.006, odds ratio=1.222, 95% CI=1.060-
1.409). Removing baseline HDRS from the model would result in a significant worsening of 
model fit (-2 LL change=10.040, p=.002). MCI type, DWMH load, PVH load, age, sex, site, and 
years of education were not were associated with response in any steps of the model. 
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For the vertex-wise analyses examining cortical thickness and treatment response, no 
statistically significant cortical thickness cluster differences were observed between responders 
and non-responders. There was also no interaction between MCI subtype and responder status 
in relation to cortical thickness. Baseline depression severity measured by the HDRS was 
significantly positively correlated with cortical thickness within the right hemisphere pars 
triangularis of the inferior frontal gyrus (cluster size=153.13, cluster-wise p=.0390) (Figure 9). 
 
Exploratory Hypotheses: H2: It is hypothesized that LMCI patients will have greater rates of 
nonresponse and nonremission than EMCI patients. 
In the logistic regression model of HDRS response, MCI subtype was not significantly 
associated with response in any step of the model. Similarly, in the logistic regression model of 
HDRS remission, MCI subtype was not significantly associated with remission in any step of the 
model.  
 
Exploratory Hypotheses: H3: It is hypothesized that ADAS-Cog scores will be significantly 
correlated with cortical thickness 
ADAS-Cog scores were significantly negatively correlated with cortical thickness, such 
that high scores (indicating worse general cognitive performance) were associated with lower 
thickness (Figure 10). For the left hemisphere, significant negative correlations between ADAS-
Cog and cortical thickness were found in the superior frontal gyrus (cluster size=327.14, cluster-
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wise p=.0010), precentral gyrus (cluster size=240.60, cluster-wise p=.0050), and rostral middle 
frontal gyrus (cluster size=154.61, cluster-wise p=.0423). For the right hemisphere, significant 
negative correlations between ADAS-Cog and cortical thickness were found in the precentral 
gyrus (cluster size=331.02, cluster-wise p=.0002) and postcentral gyrus (cluster size=140.18, 
cluster-wise p=.0433). 
 
Post Hoc Analyses: Hyperintensity Volume and Treatment Outcomes 
In the original logistic regression models of HDRS remission and HDRS response, 
hyperintensity burden were entered as categorical variables based off Fazekas ratings (DWMH 
load and PVH load). To determine if hyperintensity burden was associated with treatment 
outcome when modeled as continuous variables, binary logistic regression models of HDRS 
remission and HDRS response were rerun with DWM load and PVH load (as indicated by 
Fazekas ratings) replaced with DWMH volume and PVH volume (as obtained by the MRIcro 
semi-automated method) as covariates.  
For the logistic regression model evaluating HDRS remission, in step 0, the final step of 
the model, no predicters were entered, resulting in a ‘null model’ with the intercept only. The 
model correctly predicted 63.6% of cases as responders (β=.560, SE=.280, p=.046, odds 
ratio=1.750). MCI type, DWMH volume, PVH volume, age, sex, site, years of education, and 
baseline HDRS did not result in a significant improvement in model fit during step 1 and were 
not associated with remission in any step of the model.  
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For the logistic regression model evaluating HDRS response, in step 0 of the model, no 
predicters were entered, resulting in a ‘null model’ with the intercept only. The model correctly 
predicted 63.6% of cases as responders (β=.560, SE=.280, p=.046, odds ratio=1.750). In step 1, 
the final step of the model, baseline HDRS was entered with an overall -2 LL model fit of 62.063 
(β=-3.930, SE=1.614, p=.015, odds ratio=.020). Greater baseline HDRS was associated with 
significantly increased likelihood of response (estimate=.200, p=.006, odds ratio=1.222, 95% 
CI=1.060-1.409). Removing baseline HDRS from the model would result in a significant 
worsening of model fit (-2 LL change=10.040, p=.002). MCI type, DWMH volume, PVH volume, 
age, sex, site, and years of education were not were associated with response in any steps of 
the model. 
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DISCUSSION 
This is the first report to describe the characteristics of EMCI versus LMCI subjects in 
patients with depressive disorder.  Our sample of older adults (M age = 68.9, SD = 9.0) 
demonstrated moderate levels of depression and met broad criteria for MCI. Risk factors such 
as family history of AD, presence of the ApoE 4 allele, and cardiovascular disease were 
commonly reported by patients. Notably, the LMCI group had worse global cognitive 
functioning and smaller right hippocampal volume than the EMCI group. WMH burden did not 
vary between LMCI and EMCI, either as measured qualitatively using the Fazekas scale or 
volumetrically using the semi-automated approach for lesion estimation.  
 
MCI Subtype Analyses 
Consistent with expectations, patients with LMCI performed worse on measures of 
global cognitive functioning. This finding is in line with previous reports in the literature. Given 
that the EMCI and LCMI groups were delineated on the basis of verbal memory performance 
level, the finding of a significant difference between these groups on ADAS-Cog and MMSE 
scores supports the notion that decline in verbal memory ability is associated with decline in 
other cognitive domains (Salmon & Bondi, 2009). Although it is unclear whether decline in 
verbal memory ability precedes or coincides with reductions in other cognitive domains, 
monitoring change in status from EMCI to LMCI may be a useful proxy for estimating decline in 
global cognitive functioning. At the domain level, those with LMCI had reduced visuospatial 
ability, semantic fluency, and delayed nonverbal memory. There was also worse olfactory 
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identification performance in the LMCI group compared to the EMCI group. This is in line with 
reports from other studies which find that olfactory impairment is linked with both incident 
LMCI and progression from LMCI to dementia, but not with incident naMCI (Roberts et al., 
2016). Despite these broad differences in cognitive abilities, the two groups did not differ with 
respect to instrumental activities of daily living. No differences between the groups were found 
for depressive severity. 
Smaller medial temporal lobe volume was predicted for patients with LMCI. Indeed, 
smaller right hippocampus volume was observed in the LMCI group, which has been reported 
by other groups (Shen et al., 2011; Zhou et al., 2014). The right hippocampus is involved in 
spatial memory whereas the left hippocampus plays a greater role in verbal memory (Burgess, 
Maguire, & O'Keefe, 2002), making it somewhat surprising that no difference was found for the 
left hippocampus, seeing as our groups were formed on the basis of verbal memory 
functioning. Visual Reproduction II, a measure of spatial memory, did differ across groups, with 
significantly worse performance in the LMCI group. Consideration should be given to the 
possibility that early volume loss in the right hippocampus alongside dysfunction in visual 
memory ability are unique characteristics of DEP-CI. Follow-up studies may need to consider 
classifying amnestic patients based on any memory modality as EMCI or LMCI, instead of verbal 
memory impairment alone. There was no group difference for volume in the entorhinal cortex, 
which is a region located within the parahippocampal gyrus. Given the susceptibility of the 
entorhinal cortex to decay earlier and at a faster rate than the hippocampus in patients with 
LMCI (Pennanen et al., 2004), and the role of the entorhinal cortex in delayed recall, it is 
unexpected to find no difference between our LMCI group and EMCI group.  That being said, 
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the entorhinal cortex is a small structure and small degrees of atrophy at the MCI stage can 
sometimes be difficult to measure accurately (Price et al., 2010). 
We hypothesized greater WMH volume amongst patients with LMCI yet found no 
differences between the groups in terms of WMH volume or Fazekas ratings. There were also 
no group differences in reported vascular problems. naMCI is generally thought to largely 
comprise vascular cognitive impairment that is often a prodrome to vascular dementia, 
whereas aMCI is thought to be more likely to indicate future transition to AD. As such, naMCI is 
presumed to have a greater occurrence of cardiovascular health problems and greater WHM 
load, while aMCI is believed to have greater temporal lobe volume reductions. This was not the 
case for our amnestic sample of EMCI and LMCI, where only temporal lobe volumes were 
different across the subtypes. Because cardiovascular disease and WMHs are strongly linked 
with executive dysfunction in DEP and CI, the equivalence of these factors across groups may 
partially explain their comparable performance on tests of executive functioning, such as Trails 
B and Stroop. This sample was selected specifically for memory complaints and patients with 
more than moderate levels of hypertension were excluded, thereby limiting the severity of 
cardiovascular disease and perhaps reducing the prevalence of MRI-defined cerebrovascular 
pathology in our sample.  
Consistent with our hypothesis, LMCI patients had significantly thinner right medial 
orbitofrontal cortex thickness than EMCI patients. The medial orbitofrontal cortex has direct 
projections to and from the hippocampus and plays an important role in learning, memory, and 
decision making (Wikenheiser & Schoenbaum, 2016). Thus, it is not surprising that this region 
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differentiates early and late forms of MCI. Reduced cortical thickness has been reported in a 
previous comparison between LMCI and EMCI, though in different regions (right superior 
prefrontal, medial temporal, posterior cingulate, and lateral parietal cortices) and in a non-
depressed sample (Ye et al., 2014). Other trials have reported cortical thinning with increasing 
severity of aMCI, though have relied on classification schemes other than the 1.0 – 1.5 SD 
cutoffs used in the present study and thus contain subtypes that are not directly comparable to 
ours (Lee et al., 2018; Yang et al., 2017).  
This study involved a sample of older adults with co-occurring depression and cognitive 
impairment. However, in the literature, these two disorders are typically kept separate. 
Research focused on MCI tends to exclude depression by excluding affective disorders (Avila et 
al., 2015; Defrancesco et al., 2014; Devanand et al., 2000), and research on late-life depression 
tends to exclude memory disorders and cognitive impairment (Sheline et al., 2012) by using a 
cutoff score for the Mini-Mental State Examination (Alexopoulos et al., 2004; Manning et al., 
2015; Pimontel et al., 2013; Reinlieb et al., 2014; Yuen et al., 2014). This creates a bias against 
the study of comorbid depression and cognitive impairment in older adults. Since there is a 
clear, commonly occurring, association between depression and MCI (Geda et al., 2008; Panza 
et al., 2010; Rozzini et al., 2008), it is important to learn more about the characteristics of 
patients presenting with both conditions. 
Previously, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) enrolled subjects 
with LMCI and EMCI who did not meet criteria for a depressive disorder (Aisen et al., 2010). In 
the ADNI dataset, the LMCI group has significantly worse ADAS-Cog performance and smaller 
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total hippocampal volume than the EMCI group (Beckett et al., 2015). The discrepant total 
hippocampal volume findings between our study and ADNI may be due to the unique 
presentation of DEP-CI, comparably lower statistical power, or differing approaches for 
obtaining hippocampal volume. Our study employed a manual segmentation approach, 
whereas Beckett et al. used a fully-automated approach, which tends to estimate greater 
overall hippocampal volumes than manual methods by expanding the hippocampal ROI to the 
adjacent white matter (Tae, Kim, Lee, Nam, & Kim, 2008). 
 
Antidepressant Treatment Outcomes 
 Consistent with our prediction that reduced cortical thickness would be associated with 
poor treatment outcome, decreased left medial orbitofrontal cortex and right superior frontal 
gyrus thickness were associated with nonremission of depressive symptoms. This finding is in 
line with previous trials in the literature. Decreased medial (Schmaal et al., 2017) and lateral 
(Liu et al., 2015) orbitofrontal cortex thickness has been reported in DEP patients compared to 
healthy controls, and decreased medial orbitofrontal cortex thickness has been identified as a 
predictor of worse outcome for late-life DEP patients undergoing problem-solving therapy 
(Mackin et al., 2013). The volumetric literature coincides with these results. Patients with late 
life DEP have lower bilateral orbitofrontal cortex volume compared to healthy controls 
(Ballmaier et al., 2004; Lai, Payne, Byrum, Steffens, & Krishnan, 2000; Ribeiz et al., 2013; Taylor 
et al., 2007), and antidepressant non-remitters have an even greater volumetric reduction 
(Ribeiz et al., 2013). Despite decreases in grey matter, the orbitofrontal cortex is more 
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metabolically active during depressive episodes. Functionally, the orbitofrontal cortex is 
involved with inhibiting and modulating emotional expression, particularly through its 
projections to the amygdala and hypothalamus (Drevets, 2007). Such overactivation is posited 
to be a compensatory mechanism to temper emotional experiences in the context of 
heightened depressive symptoms. Successful antidepressant treatment reduces the metabolic 
activity of the orbitofrontal cortex and adjacent limbic structures (Brody et al., 1999), and 
thinner cortical thickness in this region may interfere with mechanism through which 
medications alleviate depressive symptoms. When successful, antidepressants induce structural 
changes as well. In a 12-week SSRI trial for late-life DEP patients with pre and post treatment 
MRI, grey matter volume loss within the orbitofrontal cortex was associated with less 
improvement in depressive symptoms. Conversely, grey matter volume increase within the 
same period was correlated with greater improvement in depressive symptoms (Droppa et al., 
2017). The same directional relationship has been reported between remission status and 
cortical thickness in middle-aged adults with treatment-resistant depression over a 6-12 month 
period (Phillips et al., 2015). 
The superior frontal gyrus was also found to predict antidepressant remission, which 
was also in line with our hypotheses. This region is functionally and cytoarchitecturally 
heterogeneous (John et al., 2006). The lateral region of the superior frontal gyrus is comprised 
by a portion of the dorsolateral prefrontal cortex, the medial portion overlaps with the medial 
prefrontal cortex, and the posterior region is occupied by the supplementary motor area. The 
involvement of the superior frontal gyrus in antidepressant remission is potentially similar to 
the role of the orbitofrontal cortex, in that neither region is directly implicated in affective 
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experiences or negative thoughts, and instead perform regulatory functions over the limbic 
system. The superior frontal gyrus is active during emotional appraisal (Falquez et al., 2014) and 
task-switching activities (Cutini et al., 2008). In depressed patients, this region has aberrant 
resting-state functional connectivity and activation during self-referential processing (i.e., 
rumination) (Lemogne, Delaveau, Freton, Guionnet, & Fossati, 2012). Following antidepressant 
treatment, functional connectivity at rest and activation in response to self-referential words 
within the superior frontal gyrus become normalized, allowing focus to be shifted to the 
external environment and positive self-referential processing to occur. (Komulainen et al., 
2018; Wang et al., 2015). Notably, changes in activation related to self-focus precedes the 
improvement of depressive symptoms. 
Although previous antidepressant and psychotherapy trials for late life DEP have also 
reported a positive relationship between frontotemporal cortical thickness and treatment 
outcome, in contrast to the present study’s results, they did not find a relationship between 
superior frontal gyrus thickness and treatment outcome (Mackin et al., 2013; Sheline et al., 
2012). There are several possible reasons for the disparate findings. First, the present analysis is 
vertex-based instead of ROI based, allowing for detection of intra-regional clusters. Second, we 
also adjusted for multiple comparisons. Third, factors including sex, age, education, and site 
differences account for as much as a fifth of the total individual differences in cortical thickness, 
exceeding the variance accounted for by depression severity and group differences in 
remission/response status (Perlman et al., 2017). Therefore, inconsistencies in which covariates 
are accounted for between studies will greatly impact the results. Finally, samples of DEP-CI 
may exhibit unique patterns of cortical thickness compared to their non-CI peers.  
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 The process behind cortical thinning in DEP remains unclear, as does the mechanism 
driving the relationship between reduced cortical thickness and poor treatment outcome. 
Several explanations have been posited. One possibility involves glucocorticoid-mediated 
atrophy. DEP patients have a hyperactive hypothalamic-pituitary-adrenal axis and elevated 
cortisol levels, which produce neurotoxic effects. Cortisol levels are negatively correlated with 
cortical thickness in the orbitofrontal cortex of DEP patients (Liu et al., 2015). This region is 
particularly susceptible to harmful effects of cortisol due to a high concentration of 
glucocorticoid receptors (Ahima & Harlan, 1990; Webster, Knable, O'Grady, Orthmann, & 
Weickert, 2002). Taken together, endocrine dysfunction in DEP might be producing atrophy in 
frontal areas (manifesting as reduced volume and cortical thickness), that in turn inhibits mood 
regulation, thus interfering with the restorative actions of antidepressants. 
 Cortical thickness changes may also be driven (at least in part) by WMH burden. Higher 
WMH load is associated with lower cortical thickness in frontotemporal regions (Fujishima et 
al., 2014; Tuladhar et al., 2015).  Similarly, reduced orbitofrontal cortex volume is also met with 
greater severity of WMH (Taylor et al., 2007). WMHs disrupt the axons corresponding to 
cortical neurons and may lead to cortical atrophy by the process of retrograde degeneration (in 
the proximal cell body). Alternatively, cortical atrophy may lead to WMHs through anterograde 
degeneration, where the distal axon becomes separated from metabolic support from the cell 
body (Mortamais, Artero, & Ritchie, 2013). As is the case with research on DEP and HPA axis 
functioning, research on the relationship between grey matter and WMH to date has been 
correlational in nature and neither the directionality nor independence of this relationship from 
other factors (e.g., aging, other vascular risk factors, neurodegenerative disorders) can be 
MRI cortical thinning and treatment outcome in comorbid depression and cognitive impairment 48 
 
 
inferred. Even so, because both cortical thickness and WMH impact antidepressant 
effectiveness, they should be examined concurrently to best identify individuals who are at risk 
for poor treatment outcome. 
 Lastly, cortical thickness-mediated antidepressant outcomes may relate to serotonin 1A 
(5-HT1A) receptor binding. Elevated 5-HT1A receptor density is seen in DEP patients relative to 
controls and results in deficient synaptic serotonin levels. Serotonin deficiency leads to reduced 
serotonin release, lower probability of post-synaptic signaling, and loss of dendrites on the pre 
and post synaptic neurons (Azmitia, 2001). These processes affect cortical thickness, as it 
depends on the size and density of neurons. 5-HT1A receptor binding correlates with posterior 
cingulate cortex thickness in DEP patients (Pillai et al., 2018). While this relationship holds 
promise for understanding processes behind cortical thinning, the brain regions linking 5-HT1A 
receptor binding with cortical thinning do not overlap with those found to predict 
antidepressant outcome. Additionally, if 5-HT1A receptor does mediate the relationship 
between cortical thickness and antidepressant outcome, it would likely apply only to a subset of 
the DEP population, as previous trials have found cortical thickness increases using diverse 
classes of antidepressants (Phillips et al., 2015). 
 WMHs were expected to be associated with worse antidepressant treatment outcome. 
Contrary to our hypothesis, greater DWMH burden (as assessed by qualitative ratings) was 
linked with greater chance of remission. This is surprising, as previous trials have reported the 
opposite relationship between WMH burden and remission (Alexopoulos et al., 2008; Gunning-
Dixon et al., 2010; Sneed et al., 2011). However, when DWMH volume was substituted for 
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DWHM qualitative ratings in the model, no significant relationship was found. The lack of 
concordance between volumetric and qualitative ratings of DWMH as they pertain to 
antidepressant remission calls into question the validity of the observed relationship between 
DWMH qualitative ratings and remission. Moreover, there was no significant relationship 
between DWMH burden and response, nor was there a relationship between PVH burden and 
either remission or response (for both volumetric and qualitative ratings). Nonetheless, while it 
is premature to conclude there is a beneficial impact of DWMH on antidepressant outcome in 
DEP-CI patients without further replication, the present findings suggest that DWMHs behave 
differently in aMCI vs naMCI samples. 
MCI status (as determined by severity of amnestic deficit) was also not a significant 
predictor of antidepressant outcome. Co-morbid amnestic deficits have not been previously 
explored with respect to treatment effectiveness is DEP samples. One possibility for the null 
finding is that the present sample is restricted to patients with amnestic deficits, and analyses 
on the severity of existing amnestic deficits might not be as sensitive for detecting impact on 
response as would analyses comparing patients with and without amnestic deficits. Cognitive 
deficits in other domains, such as executive functioning and processing speed, have been linked 
with poor antidepressant outcomes (G. S. Alexopoulos et al., 2005; Sheline et al., 2012; Sneed, 
Keilp, Brickman, & Roose, 2008; Sneed et al., 2007). 
 
Exploratory Cortical Thickness Analyses 
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 As predicted, worse ADAS-Cog performance was associated with reduced cortical 
thickness, specifically in the left hemisphere superior frontal, precentral, and rostral middle 
frontal gyri, and right hemisphere precentral and postcentral gyri. The diffuse cortical areas 
associated with ADAS-Cog performance owes to the multitude of tasks that comprise this 
instrument, such as word recall, object naming, constructional praxis, and language.  Measures 
of global cognitive functioning such as the ADAS-Cog and MMSE are sensitive to generalized 
cortical atrophy due to neurodegenerative disease progression (Evans et al., 2010; Kovacevic, 
Rafii, Brewer, & the Alzheimer's Disease Neuroimaging, 2009; Leow et al., 2009; C. Li et al., 
2011).  
 
Limitations 
The DEP-CI subjects presented in this report were enrolled in a longitudinal trial to test 
the efficacy of combined antidepressant and donepezil therapy versus antidepressant alone. 
This study contains several limitations balanced by its unique strengths. Notably, the exclusive 
use of memory tests to determine eligibility precludes the sample from representing the full 
range of possible non-amnestic MCI subtypes. Exclusion of more than moderate levels of 
hypertension limits the presentations of MCI due to cerebrovascular disease. Nonetheless, the 
broad inclusion and exclusion criteria for depression and amnestic cognitive impairment 
increases generalizability to clinical settings.   
In addition to having a limited range of the possible MCI subtypes, this study shares 
similar issues endemic in all trials that use EMCI and LMCI classifications. To be classified as 
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EMCI, patients must have expressed subjective memory or other cognitive impairments and 
had a score between 1.0 to 1.5 SDs below the mean on the Logical Memory II test (Delayed 
Paragraph Recall) or on the Free and Cued Selective Reminding Test (Immediate or Delayed 
Recall). Assuming a normal distribution of scores in the population, a score 1.0 SDs below the 
mean corresponds to the 16th percentile rank, meaning that a sizable portion of the population 
fits within the EMCI range irrespective of actual decline in memory functioning due to early 
features of a neurodegenerative disorder. The requirement of a subjective report of cognitive 
decline alongside the 1.0 SD below the mean minimum cutoff is intended to reduce to 
likelihood that participants meet inclusion criteria solely based on low premorbid abilities. 
Subjective cognitive complaints have small though significant independent associations with 
both objective cognitive functioning and depressive symptoms (Burmester, Leathem, & 
Merrick, 2016). However, the possibility that some EMCI participants’ measured performance 
fell within the 1.0-1.5 SD below the mean range without any true decline from their baseline 
cannot be conclusively ruled out. This is also true for participants within the LMCI group, 
though to a lesser extent as a score 1.5 SDs below the mean corresponds to the 7th percentile 
rank. Other extraneous factors, such as poor motivation, concurrent illness, and fatigue can 
result in temporarily low testing performance that change with time. Thus, the sample is 
potentially heterogenous by including participants who are cognitive healthy alongside 
participants with decline due to early stages of a neurodegenerative disorder. Indeed, many 
individuals diagnosed with MCI return to cognitively normal status or remain stable without 
conversion to AD or other dementia (Sachdev et al., 2013), with estimates for the rate of 
reversion over 1-2 years varying from 4.5% (Nordlund et al., 2010) to 53% (Ganguli et al., 2011) 
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across studies. Although repeated neuropsychological testing can aid with differentiating those 
who are cognitively stable from those who have experienced a decline from their baseline, this 
data was not collected during the acute phase of antidepressant treatment. Alternatively, 
requiring objective reductions on multiple neuropsychological tests can reduce the rate of false 
positive MCI diagnoses. Patients who have mildly impaired performance on multiple measures 
are more likely to be correctly identified as MCI by retaining at least that level of impairment 
over two years (Klekociuk, Summers, Vickers, & Summers, 2014).  
In the current study, multiple memory measures were employed, though patients were 
required to reach mild impairment on only one of them to be enrolled. The use of multiple 
memory tests during participant screening is suitable for capturing a wider array of amnestic 
presentations, though comes at the cost of memory deficit specificity. To elaborate, the two 
measures used for inclusion criteria, although both involving verbal memory, are unique in their 
content. The Logical Memory II test (Delayed Paragraph Recall) involves delayed free recall of 
context-dependent information structured in the form of a story. Although there is an 
immediate free recall trial as part of the Logical Memory I test, only performance on the 
delayed free recall Logical Memory II test was used for inclusion criteria. On the other hand, the 
Free and Cued Selective Reminding Test involves context-independent information in the form 
of a word-list. This test has both immediate and delayed recall, both with free and cued recall 
trials. Both the immediate and delayed recall trials were used for inclusion criteria. Although 
delayed free recall tests of context-independent and context-dependent information are 
comparable in their sensitivity and specificity for differentiating MCI patients from cognitively 
healthy individuals, comparisons of the diagnostic accuracy of immediate free recall tests have 
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found better sensitivity and specificity for context-independent information over context-
dependent information (Weissberger et al., 2017). The use of only delayed recall trials of 
context-dependent information, but both immediate and delayed trials of context-independent 
information is problematic, in that it allows for representation of amnestic deficits stemming 
from both encoding and retrieving of list information, but only from retrieval of story 
information. Context-dependent and context independent information are processed 
differently (Barsalou, 1982), with each type depending on the hippocampus as well as their own 
separate cortical regions.  Performance on context-independent memory tests is linked with 
executive functioning and depends on frontal lobe integrity (Kopelman & Stanhope, 1998; 
Tremont, Halpert, Javorsky, & Stern, 2000), whereas content-independent memory 
performance is more strongly predicated on broader temporal lobe functioning (Lezak, 
Howieson, Bigler, & Tranel, 2012; Tremont et al., 2000). Thus, unequal representation of 
memory content within the patient selection tools may have affected the clinical characteristics 
of the resulting sample. 
 
Future Directions 
Further longitudinal studies to examine clinical, genetic, neuronal loss, and pathological 
markers of AD in subjects with and without comorbid depression and cognitive impairment are 
warranted to assess possible interaction of these factors.  Such studies may provide critical 
information to develop personalized treatment for patients with DEP-CI and may provide 
additional insights to delay the onset of dementia. When establishing predictors for dementia 
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onset or antidepressant response, single anatomical features are not as accurate as multiple 
features used concurrently (Weiner et al., 2015). Cortical thickness, volume, and surface area 
are components that measure the integrity of the cerebral cortex, though each contributes 
complementary information, and therefore should be evaluated concurrently through 
multivariate analyses. While identifying clusters of reduced grey matter is useful for detecting 
brain regions driving DEP-CI, the role of these areas as they relate to one another and 
contribute to wider neural network functioning will be more useful than defining each region in 
isolation. The interrelation between the hippocampus and orbitofrontal cortex has particular 
relevance for DEP-CI. Understanding the impact of these brain abnormalities on treatment 
outcomes has the potential to significantly improve the prognosis for individuals with DEP-CI by 
identifying individuals who are at risk for poor treatment outcomes. In addition to guiding 
treatment selection, better understanding of the pathology driving DEP-CI will inform the 
development of more effective interventions. 
 
Conclusions 
 In summary, the current project represents an assessment of clinical, cognitive, and 
anatomical characteristics of aMCI subtypes, as well as predictors of acute antidepressant 
outcome. The results of this study support the premise that EMCI and LMCI differ on global 
cognition, hippocampal volume, and cortical thickness within the right orbitofrontal cortex. 
Reduced cortical thickness in the left orbitofrontal cortex predicted reduced likelihood of 
remission. WMHs were not prognostic indicators of poor treatment outcome. Taken together, 
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individuals with DEP-CI exhibit unique patterns of structural abnormalities compared to their 
non-CI peers that have consequences for their recovery and may complicate their risk of 
progression to later neurodegenerative diseases. 
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APPENDIX A: TABLES 
Table 1. Baseline demographic and clinical characteristic comparisons between EMCI and LMCI 
Demographic Variable All Patients 
(n=79) 
EMCI 
(n=39) 
LMCI 
(n=40) 
t Test/Chi Square 
Site 
   NYSPI 
   DU 
 
39 (49.4%) 
40 (50.6%) 
 
15 (38.5%) 
24 (61.5%) 
 
24 (60.0%) 
16 (40.0%) 
χ2=3.7, p=.056 
Age 68.9 (9.0) 67.5 (8.6) 70.2 (9.2) t=-1.3, p=.185 
Sex 
   Male 
   Female 
 
41 (51.9%) 
38 (48.1%) 
 
18 (46.2%) 
21 (53.8%) 
 
23 (57.5%) 
17 (42.5%) 
χ2=1.0, p=.313 
Education 15.3 (2.8) 15.3 (3.2) 15.3 (2.3) t=.1, p=.946 
Race 
   Caucasian 
   Black/African American 
   Hispanic 
 
58 (73.4%) 
12 (15.2%) 
9 (11.4%) 
 
32 (82.1%) 
5 (12.8%) 
2 (5.1%) 
 
26 (65.0%) 
7 (17.5%) 
7 (17.5%) 
χ2=3.7, p=.156 
Marital Status 
   Single/never married 
   Divorced/separated 
   Married/living with partner 
   Widowed 
 
28 (35.4%) 
19 (24.1%) 
23 (29.1%) 
9 (11.4%) 
 
9 (23.1%) 
10 (25.6%) 
15 (38.5%) 
5 (12.8%) 
 
19 (47.5%) 
9 (22.5%) 
8 (20.0%) 
4 (10.0%) 
χ2=5.9, p=.119 
Employment 
   Working 
   Retired 
   Unemployed/Disabled 
 
29 (36.7%) 
37 (46.8%) 
13 (16.5%) 
 
16 (41.0%) 
17 (43.6%) 
6 (15.4%) 
 
12 (32.5%) 
20 (50.0%) 
7 (17.5%) 
χ2=.6, p=.734 
ADAS-Cog Total 14.3 (5.4) 12.0 (4.5) 16.6 (5.3) t=-4.2, p<.001 
HDRS 23.0 (5.1) 23.2 (5.5) 22.9 (4.8) t=.3, p=.776 
Family History of Depression 
   No 
   Yes 
 
39 (49.4%) 
40 (50.6%) 
 
18 (46.2%) 
21 (53.8%) 
 
21 (52.5%) 
19 (47.5%) 
χ2=0.3, p=.573 
Family History of Dementia 
   No 
   Yes 
 
43 (54.4%) 
36 (45.6%) 
 
22 (56.4%) 
17 (43.6%) 
 
21 (52.5%) 
19 (47.5%) 
χ2=.1, p=.757 
Family History of Alzheimer’s 
   No 
   Yes 
 
66 (83.5%) 
13 (16.5%) 
 
34 (87.2%) 
5 (12.8%) 
 
32 (80.0%) 
8 (20.0%) 
χ2=.7, p=.390 
CIRS Total  7.4 (4.2) 8.1 (4.3) 6.7 (4.0) t=1.6, p=.120 
   Vascular Problems 
      No 
      Yes 
 
51 (64.6%) 
28 (35.4%) 
 
28 (71.8%) 
11 (28.2%) 
 
23 (57.5%) 
17 (42.5%) 
χ2=1.8, p=.184 
FAQ Patient 4.0 (3.5) 3.9 (3.8) 4.1 (3.2) t=-.3, p=.775 
FAQ Informant 3.1 (4.0) 2.7 (4.2) 3.6 (3.9) t=-1.0, p=.326 
ApoE genotype  
   ApoE allele not present 
   ApoE allele present 
 
51 (64.6%) 
23 (29.1%) 
 
25 (69.4%) 
11 (30.6%) 
 
26 (68.4%) 
12 (31.6%) 
χ2=.01, p=.924 
All values expressed as mean (SD) or n (%) 
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Table 2. Baseline demographic and clinical characteristic comparisons between patients with and without MRI 
scans 
Demographic Variable All Patients 
(n=79) 
MRI 
Patients 
(n=55) 
Non-MRI 
Patients 
(n=24) 
t Test/Chi Square 
Site 
   NYSPI 
   DU 
 
39 (49.4%) 
40 (50.6%) 
 
28 (50.9%) 
27 (49.1%) 
 
11 (45.8%) 
13 (54.2%) 
χ2=.2, p=.678 
Age 68.9 (9.0) 68.4 (8.5) 70.0 (10.0) t=.7, p=.481 
Sex 
   Male 
   Female 
 
41 (51.9%) 
38 (48.1%) 
 
32 (58.2%) 
23(41.8%) 
 
14 (58.3%) 
10 (41.7%) 
χ2=1.8, p=.176 
Education 15.3 (2.8) 15.4 (3.0) 15.0 (2.3) t=-.6, p=.523 
Race 
   Caucasian 
   Black/African American 
   Hispanic 
 
58 (73.4%) 
12 (15.2%) 
9 (11.4%) 
 
40 (72.7%) 
8 (14.5%) 
7 (12.7%) 
 
18 (75.0%) 
4 (16.7%) 
2 (8.3%) 
χ2=.3, p=.842 
Marital Status 
   Single/never married 
   Divorced/separated 
   Married/living with partner 
   Widowed 
 
28 (35.4%) 
19 (24.1%) 
23 (29.1%) 
9 (11.4%) 
 
23 (41.8%) 
11 (20.0%) 
18 (32.7%) 
3 (5.5%) 
 
5 (20.8%) 
8 (33.3%) 
5 (20.8%) 
6 (25.0%) 
χ2=9.7, p=.021 
Employment 
   Working 
   Retired 
   Unemployed/Disabled 
 
29 (36.7%) 
37 (46.8%) 
13 (16.5%) 
 
19 (34.5%) 
26 (47.3%) 
10 (18.2%) 
 
10 (41.7%) 
11 (45.8%) 
3 (12.5%) 
χ2=.6, p=.754 
ADAS-Cog Total 14.3 (5.4) 14.4 (5.8) 14.1 (4.3) t=-.3, p=.791 
HDRS 23.0 (5.1) 23.2 (5.4) 22.8 (4.5) t=-.3, p=.743 
Family History of Depression 
   No 
   Yes 
 
39 (49.4%) 
40 (50.6%) 
 
26 (47.3%) 
29 (52.7%) 
 
13 (54.2%) 
11 (45.8%) 
χ2=.3, p=.573 
Family History of Dementia 
   No 
   Yes 
 
43 (54.4%) 
36 (45.6%) 
 
29 (52.7%) 
26 (47.3%) 
 
14 (58.3%) 
10 (41.7%) 
χ2=.2, p=.645 
Family History of Alzheimer’s 
   No 
   Yes 
 
66 (83.5%) 
13 (16.5%) 
 
47 (85.5%) 
8 (14.5%) 
 
19 (79.2%) 
5 (20.8%) 
χ2=.5, p=.488 
CIRS Total  7.4 (4.2) 7.2 (3.7) 7.8 (5.2) t=-.6, p=.570 
   Vascular Problems 
      No 
      Yes 
 
51 (64.6%) 
28 (35.4%) 
 
37 (67.3%) 
18 (32.7%) 
 
14 (58.3%) 
10 (41.7%) 
χ2=.6, p=.445 
FAQ Patient 4.0 (3.5) 4.0 (3.6) 4.0 (3.4) t=.1, p=.928 
FAQ Informant 3.1 (4.0) 3.4 (4.4) 2.4 (2.8) t=-.9, p=.360 
ApoE genotype  
   ApoE allele not present 
   ApoE allele present 
 
51 (64.6%) 
23 (29.1%) 
 
39 (72.2%) 
15 (27.8%) 
 
12 (60.0%) 
8 (40.0%) 
χ2=1.0, p=.313 
All values expressed as mean (SD) or n (%) 
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Table 3. Baseline demographic and clinical characteristic comparisons between remitters and non-remitters 
Demographic Variable All MRI 
Patients 
(n=55) 
Non-
remitters 
(n=40) 
Remitters 
(n=15) 
t Test/Chi Square 
Site 
   NYSPI 
   DU 
 
28 (50.9%) 
27 (49.1%) 
 
20 (50.0%) 
20 (50.0%) 
 
8 (53.3%) 
7 (46.7%) 
χ2=.5, p=.826 
Age 68.4 (8.5) 69.4 (9.2) 65.9 (5.7) t=1.4, p=.179 
Sex 
   Male 
   Female 
 
32 (58.2%) 
23(41.8%) 
 
15 (37.5%) 
25 (62.5%) 
 
7 (46.7%) 
8 (53.3%) 
χ2=1.1, p=.289 
Education 15.4 (3.0) 15.2 (3.1) 16.0 (2.7) t=-.9, p=.392 
Race 
   Caucasian 
   Black/African American 
   Hispanic 
 
40 (72.7%) 
8 (14.5%) 
7 (12.7%) 
 
31 (77.5%) 
5 (12.5%) 
4 (10.0%) 
 
9 (60.0%) 
3 (20.0%) 
3 (20.0%) 
χ2=1.7, p=.419 
Marital Status 
   Single/never married 
   Divorced/separated 
   Married/living with partner 
   Widowed 
 
23 (41.8%) 
11 (20.0%) 
18 (32.7%) 
3 (5.5%) 
 
16 (40.0%) 
7 (17.5%) 
15 (37.5%) 
2 (5.0%) 
 
7 (46.7%) 
4 (26.7%) 
3 (20.0%) 
1 (6.7%) 
χ2=1.7, p=.648 
Employment 
   Working 
   Retired 
   Unemployed/Disabled 
 
19 (34.5%) 
26 (47.3%) 
10 (18.2%) 
 
14 (35.0%) 
18 (45.0%) 
8 (20.0%) 
 
5 (33.3%) 
8 (53.3%) 
2 (13.3%) 
χ2=.4, p=.804 
ADAS-Cog Total 14.4 (5.8) 13.7 (5.8) 16.4 (5.5) t=-1.6, p=.127 
HDRS 23.2 (5.4) 23.4 (5.7) 22.5 (4.7) t=.5, p=.599 
Family History of Depression 
   No 
   Yes 
 
26 (47.3%) 
29 (52.7%) 
 
17 (42.5%) 
23 (57.5%) 
 
9 (60.0%) 
6 (40.0%) 
χ2=1.3, p=.247 
Family History of Dementia 
   No 
   Yes 
 
29 (52.7%) 
26 (47.3%) 
 
21 (52.5%) 
19 (47.5%) 
 
8 (53.3%) 
7 (46.7%) 
χ2=.0, p=.956 
Family History of Alzheimer’s 
   No 
   Yes 
 
47 (85.5%) 
8 (14.5%) 
 
35 (87.5%) 
5 (12.5%) 
 
12 (80.0%) 
3 (20.0%) 
χ2=.5, p=.482 
CIRS Total  7.2 (3.7) 7.3 (3.8) 6.9 (3.8) t=.3, p=.750 
   Vascular Problems 
      No 
      Yes 
 
37 (67.3%) 
18 (32.7%) 
 
26 (65.0%) 
14 (35.0%) 
 
11 (73.3%) 
4 (26.7%) 
χ2=.3, p=.557 
FAQ Patient 4.0 (3.6) 3.8 (3.3) 4.3 (4.5) t=-.5, p=.645 
FAQ Informant 3.4 (4.4) 2.9 (3.7) 4.8 (5.7) t=-1.5, p=.146 
ApoE genotype  
   ApoE allele not present 
   ApoE allele present 
 
39 (72.2%) 
15 (27.8%) 
 
31 (79.5%) 
8 (20.5%) 
 
8 (53.3%) 
7 (46.7%) 
χ2=3.7, p=.055 
All values expressed as mean (SD) or n (%) 
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Table 4. Baseline demographic and clinical characteristic comparisons between responders and non-responders 
Demographic Variable All MRI 
Patients 
(n=55) 
Non-
responders 
(n=20) 
Responders 
(n=35) 
t Test/Chi 
Square 
Site 
   NYSPI 
   DU 
 
28 (50.9%) 
27 (49.1%) 
 
11 (55.0%) 
9 (45.0%) 
 
17 (48.6%) 
18 (51.4%) 
χ2=.2, p=.646 
Age 68.4 (8.5) 71.6 (9.8) 66.6 (7.2) t=2.1, p=.037 
Sex 
   Male 
   Female 
 
32 (58.2%) 
23(41.8%) 
 
7 (35.0%) 
13 (65.0%) 
 
16 (45.7%) 
19 (54.3%) 
χ2=.6, p=.438 
Education 15.4 (3.0) 15.3 (2.3) 15.5 (3.2) t=-.3, p=.799 
Race 
   Caucasian 
   Black/African American 
   Hispanic 
 
40 (72.7%) 
8 (14.5%) 
7 (12.7%) 
 
18 (90.0%) 
1 (5.0%) 
1 (5.0%) 
 
22 (62.9%) 
7 (20.0%) 
6 (17.1%) 
χ2=4.7, p=.094 
Marital Status 
   Single/never married 
   Divorced/separated 
   Married/living with partner 
   Widowed 
 
23 (41.8%) 
11 (20.0%) 
18 (32.7%) 
3 (5.5%) 
 
8 (40.0%) 
3 (15.0%) 
7 (35.0%) 
2 (10.0%) 
 
15 (42.9%) 
8 (22.9%) 
11 (31.4%) 
1 (2.9%) 
χ2=1.7, p=.646 
Employment 
   Working 
   Retired 
   Unemployed/Disabled 
 
19 (34.5%) 
26 (47.3%) 
10 (18.2%) 
 
7 (35.0%) 
9 (45.0%) 
4 (20.0%) 
 
12 (34.3%) 
17 (48.6%) 
6 (17.1%) 
χ2=.9, p=.954 
ADAS-Cog Total 14.4 (5.8) 13.9 (6.5) 14.8 (5.5) t=-.6, p=.577 
HDRS 23.2 (5.4) 20.4 (4.4) 24.8 (5.3) t=-3.2., p=.003 
Family History of Depression 
   No 
   Yes 
 
26 (47.3%) 
29 (52.7%) 
 
9 (45.0%) 
11 (55.0%) 
 
17 (48.6%) 
18 (51.4%) 
χ2=.7, p=.799 
Family History of Dementia 
   No 
   Yes 
 
29 (52.7%) 
26 (47.3%) 
 
10 (50.0%) 
10 (50.0%) 
 
19 (54.3%) 
16 (45.7%) 
χ2=.1, p=.759 
Family History of Alzheimer’s 
   No 
   Yes 
 
47 (85.5%) 
8 (14.5%) 
 
18 (90.0%) 
2 (10.0%) 
 
29 (82.9%) 
6 (17.1%) 
χ2=.5, p=.470 
CIRS Total  7.2 (3.7) 7.0 (3.6) 7.3 (3.9) t=-.4., p=.712 
   Vascular Problems 
      No 
      Yes 
 
37 (67.3%) 
18 (32.7%) 
 
15 (75.0%) 
5 (25.0%) 
 
22 (62.9%) 
13 (37.1%) 
χ2=.9, p=.356 
FAQ Patient 4.0 (3.6) 3.4 (3.5) 4.3 (3.7) t=-1.0, p=.344 
FAQ Informant 3.4 (4.4) 2.2 (3.9) 4.1 (4.6) t=-1.5, p=.134 
ApoE genotype  
   ApoE allele not present 
   ApoE allele present 
 
39 (72.2%) 
15 (27.8%) 
 
15 (78.9%) 
4 (21.1%) 
 
24 (68.6%) 
11 (31.4%) 
χ2=.7, p=.416 
All values expressed as mean (SD) or n (%) 
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Table 5. ANCOVA of neuropsychological measures 
Instrument All Patients 
(n=79) 
EMCI 
(n=39) 
LMCI 
(n=40) 
F-Ratio P-Value Effect Size 
Folstein MMSE 27.9 (2.0) 28.5 (1.7) 27.3 (2.1) F(1,73)=8.7 p=.004 ηp2=.106 
WAIS-III Block Design 31.2 (11.3) 34.1 (11.3) 28.3 (10.7) F(1,73)=5.4 p=.024 ηp2=.069 
WAIS-R Digit Symbol 42.0 (12.2) 45.0 (12.5) 39.1 (10.1) F(1,73)=3.5 p=.065 ηp2=.046 
CFL Letter Total 40.3 (12.4) 42.8 (11.0) 38.0 (13.4) F(1,73)=3.4  p=.069 ηp2=.045 
CFL Animal Total 17.5 (4.6) 19.0 (4.7) 16.0 (4.2) F(1,73)=8.1 p=.006 ηp2=.100 
Stroop Interference -2.3 (8.5) -1.4 (6.7) -3.3 (10.0) F(1,73=1.1 p=.290 ηp2=.015 
WMS-R Visual Rep I 32.1 (5.8) 32.9 (6.0) 31.2 (5.6) F(1,73)=1.7 p=.198 ηp2=.023 
WMS-R Visual Rep II 23.7 (11.1) 27.2 (10.2) 20.3 (10.9) F(1,73)=8.0 p=.006 ηp2=.099 
Trails A 46.6 (20.1) 44.6 (21.9) 48.7 (18.3) F(1,73)=.1 p=.710 ηp2=.002 
Trails B 130.0 (64.5) 120.9 (63.3) 138.8 (65.2) F(1,73)=.7 p=.418 ηp2=.009 
BNT Total Correct 14.5 (1.1) 14.6 (1.1) 14.4 (1.1) F(1,73)=.5 p=.484 ηp2=.007 
UPSIT 29.4 (7.7) 31.6 (7.7) 27.2 (7.3) F(1,73)=3.9 p=.051 ηp2=.052 
All values expressed as mean (SD) 
Note: All models are adjusted for age, sex, HDRS, and years of education 
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Table 6. ANCOVA and logistic regression of MRI lesions and brain tissue volumes 
Measurement MRI Patients 
(n=55) 
EMCI 
(n=24) 
LMCI 
(n=31) 
F-ratio/Wald 
test 
P-Value Effect 
Size 
Fazekas hyperintensity rating       
   Deep white matter 
      Low (0-1) 
      High (2-3) 
 
46 (83.6%) 
9 (16.4%) 
 
20 (83.3%) 
4 (16.7%) 
 
26 (83.9%) 
5 (16.1%) 
Wald=.2 p=.656 OR=.647 
   Periventricular 
      Low (0-1) 
      High (2-3) 
 
30 (54.5%) 
25 (45.5%) 
 
16 (66.7%) 
8 (33.3%) 
 
14 (45.2%) 
17 (54.8%) 
Wald=1.4 p=.244 OR=2.103 
Hyperintensity volume(cc)       
   Deep white volume 5.6 (11.7) 3.8 (11.4) 7.0 (12.0) F(1,49)=.9 p=.338 ηp2=.019 
   Periventricular volume 28.5 (45.0) 24.2 (43.5) 31.8 (46.6) F(1,49)=.7 p=.797 ηp2=.001 
Brain volume(cc)       
   Total hippocampus 4.9 (0.7) 5.1 (0.6) 4.8 (0.7) F(1,49)=2.1 p=.157 ηp2=.040 
   Right hippocampus 1.9 (0.3) 2.0 (0.3) 1.9 (0.2) F(1,49)=4.6 p=.037 ηp2=.085 
   Left hippocampus 3.0 (0.4) 3.1 (0.4) 2.9 (0.5) F(1,49)=.8 p=.380 ηp2=.015 
   Right parahippocampal gyrus 2.0 (0.4) 2.1 (0.3) 1.9 (0.4) F(1,49)=2.0 p=.164 ηp2=.038 
   Left parahippocampal gyrus 3.1 (0.5) 3.2 (0.4) 3.0 (0.5) F(1,49)=1.3 p=.260 ηp2=.025 
   Right entorhinal cortex 0.2 (0.03) 0.2 (0.04) 0.1 (0.03) F(1,49)=.5 p=.464 ηp2=.004 
   Left entorhinal cortex 0.2 (0.03) 0.2 (0.04) 0.2 (0.03) F(1,49)=.1 p=.864 ηp2=.001 
All values expressed as mean (SD) or n (%) 
Note: All models are adjusted for age, sex, HDRS, and years of education 
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Table 7. Vertex-wise cortical thickness group analyses 
Region Cluster Size (mm2) # of Vertices x y z CWP 
Remitters > Non-remitters 
L Medial Orbitofrontal Cortex 160.55 292 -10.7 38.8 -5.2 .0269 
 R Superior Frontal Gyrus 152.51 324 7.5 26.4 51.4 .0315 
EMCI > LMCI 
R Medial Orbitofrontal Cortex 139.42 263 10.0 32.7 -18.4 .0438 
 
Effects with significant clusterwise-values after correcting for multiple comparisons using monte carlo 
simulations with a vertex-level primary threshold: p<0.001 and cluster-level extent threshold: p<0.05. All 
analyses were additionally covaried for site, sex, age, baseline HDRS, MCI subtype, and years of education. X, Y, Z 
coordinates represent peak-coordinates within the MNI305 reference frame. Abbreviations: R=right; L=left; 
CWP=clusterwise p-value. 
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Table 8. Parameter Estimates for Final Stepwise Logistic Regression Model Evaluating HDRS Remission 
 Estimate Standard Error Wald (df) p Odds Ratio 95% CI 
Intercept 6.837 3.580 3.647(1) .056 931.853  
Age -.091 .048 3.575(1) .059 .913 .831 – 1.003 
DWMH Load -2.141 .903 5.624(1) .018 .117 .020 – .690 
 
HDRS remission was entered as the dependent variable. Site, sex, age, years of education, baseline HDRS, MCI 
subtype, DWMH load, and PVH load were entered sequentially as covariates. After each change to the model, 
difference in -2 Log Likelihoods (-2LL) from the previous model was used to test for improved fit. Covariates that 
did not incur a significant reduction in -2 Log Likelihood were removed (measured by chi square test).  
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Table 9. Parameter Estimates for Final Stepwise Logistic Regression Model Evaluating HDRS Response 
 Estimate Standard Error Wald (df) p Odds Ratio 95% CI 
Intercept -3.930 1.614 5.930(1) .015 .020  
Baseline HDRS .200 .073 7.586(1) .006 1.222 1.060 – 1.409 
 
HDRS response was entered as the dependent variable. Site, sex, age, years of education, baseline HDRS, MCI 
subtype, DWMH load, and PVH load were entered sequentially as covariates. After each change to the model, 
difference in -2 Log Likelihoods (-2LL) from the previous model was used to test for improved fit. Covariates that 
did not incur a significant reduction in -2 Log Likelihood were removed (measured by chi square test).  
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Table 10. Vertex-wise cortical thickness correlational analyses 
Region Cluster Size (mm2) # of Vertices x y z CWP 
Baseline HDRS/Average Thickness Correlation 
R Pars Triangularis 153.13 238 49.6 31.9 -7.3 .0390 
Baseline ADAS-Cog/Average Thickness Correlation 
L Superior Frontal Gyrus 327.14 625 -20.9 34.1 28.4 .0010 
L Precentral Gyrus 240.60 571 -22.7 -23.5 48.7 .0050 
L Rostral Middle Frontal Gyrus 154.61 243 -34.1 35.7 24.2 .0423 
R Precentral Gyrus 331.02 559 42.7 1.1 32.2 .0002 
R Postcentral Gyrus 140.18 289 47.8 -20.1 49.2 .0433 
 
Effects with significant clusterwise-values after correcting for multiple comparisons using monte carlo 
simulations with a vertex-level primary threshold: p<0.001 and cluster-level extent threshold: p<0.05. All 
analyses were additionally covaried for site, sex, age, baseline HDRS, MCI subtype, and years of education. X, Y, Z 
coordinates represent peak-coordinates within the MNI305 reference frame. Abbreviations: R=right; L=left; 
CWP=clusterwise p-value. 
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APPENDIX B: FIGURES 
Figure 1. Semi-automated method of WMH volume estimation 
 
Volumetric ratings were made using the semi-automated software MRIcro 
(http://www.sph.sc.edu/comd/rorden/mricro). Four images from the volumetric procedure in MRIcro are depicted: 
(1) The original grayscale MRI axial T2 FLAIR image from a representative subject; (2) The region of interest (ROI)  
map created by semiautomatic intensity thresholding; (3) The ROI map created by gross manual outlining of 
hyperintensities; and (4) The intersection of (B) and (C) yielding hyperintensities of interest.  
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Figure 2. Classifications of DWMH Load 
 
Top left: Axial T2 FLAIR image of ‘low DWMH’ load corresponding to a Fazekas rating of 1. DWMH regions are 
highlighted using the semiautomated method in the bottom left. Top right: ‘High’ DWMH load corresponding to 
a Fazekas rating of 2. DWMH regions are highlighted in the bottom right. 
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Figure 3. Classifications of PVH Load 
 
Top left: Axial T2 FLAIR image of ‘low PVH’ load corresponding to a Fazekas rating of 1. PVH regions are 
highlighted using the semiautomated method in the bottom left. Top right: ‘High PVH’ load corresponding to a 
Fazekas rating of 3. PVH regions are highlighted in the bottom right. 
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Figure 4. Regions within the Desikan-Killany cortical labelling protocol 
 
From (Klein and Tourville (2012)) 
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Figure 5. ADAS-Cog (13 Item) by MCI subtype 
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Figure 6. Hippocampus volume by MCI subtype 
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Figure 7. Vertex-wise analysis of cortical thickness in EMCI vs. LMCI 
 
Medial and inferior view of cluster containing greater cortical thickness for EMCI compared to LMCI found in the 
right hemisphere medial orbitofrontal cortex after adjusting for multiple comparisons (vertex-level primary 
threshold: p<0.001, cluster-level extent threshold: p<0.05). Light grey features are sulci and dark grey features 
are gyri. 
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Figure 8. Vertex-wise analysis of cortical thickness in remitters vs. non-remitters 
 
Top: Medial and anterior view of cluster containing greater cortical thickness for remitters compared to non-
remitters found in the left hemisphere medial orbitofrontal cortex after adjusting for multiple comparisons 
(vertex-level primary threshold: p<0.001, cluster-level extent threshold: p<0.05). Bottom: Medial and anterior 
view of cluster containing greater cortical thickness for remitters compared to non-remitters found in right 
hemisphere superior frontal gyrus. 
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Figure 9. Baseline HDRS and cortical thickness correlation 
 
Lateral and inferior view of cluster containing a positive correlation between cortical thickness and baseline 
HDRS found in the right hemisphere pars triangularis after adjusting for multiple comparisons (vertex-level 
primary threshold: p<0.001, cluster-level extent threshold: p<0.05). 
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Figure 10. Baseline ADAS-Cog and cortical thickness correlation 
 
Top: Lateral and superior view of clusters containing a negative correlation between cortical thickness and 
baseline ASAS-Cog found in the left hemisphere superior frontal gyrus, precentral gyrus, and rostral middle 
frontal gyrus after adjusting for multiple comparisons (vertex-level primary threshold: p<0.001, cluster-level 
extent threshold: p<0.05). Bottom: Lateral and superior view of clusters containing a negative correlation 
between cortical thickness and baseline ADAS-Cog found in the right hemisphere precentral gyrus and 
postcentral gyrus.
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